WO2006115633A2 - Cyanine-chlorotoxin conjugate and method for intra-operative fluorescent visualization of cancer - Google Patents
Cyanine-chlorotoxin conjugate and method for intra-operative fluorescent visualization of cancer Download PDFInfo
- Publication number
- WO2006115633A2 WO2006115633A2 PCT/US2006/010170 US2006010170W WO2006115633A2 WO 2006115633 A2 WO2006115633 A2 WO 2006115633A2 US 2006010170 W US2006010170 W US 2006010170W WO 2006115633 A2 WO2006115633 A2 WO 2006115633A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chlorotoxin
- conjugate
- cancers
- binding
- cells
- Prior art date
Links
- 229960005534 chlorotoxin Drugs 0.000 title claims abstract description 344
- 238000000034 method Methods 0.000 title claims abstract description 54
- 206010028980 Neoplasm Diseases 0.000 title claims description 110
- 201000011510 cancer Diseases 0.000 title claims description 50
- 238000012800 visualization Methods 0.000 title abstract description 10
- QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical compound C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 claims abstract description 343
- 101710164760 Chlorotoxin Proteins 0.000 claims abstract description 341
- 238000000799 fluorescence microscopy Methods 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 118
- 230000027455 binding Effects 0.000 claims description 110
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 91
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 91
- 210000001519 tissue Anatomy 0.000 claims description 72
- 206010018338 Glioma Diseases 0.000 claims description 36
- 238000003384 imaging method Methods 0.000 claims description 30
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 24
- 208000000172 Medulloblastoma Diseases 0.000 claims description 22
- 206010060862 Prostate cancer Diseases 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 20
- 230000001613 neoplastic effect Effects 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000003937 drug carrier Substances 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 8
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical group [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims description 8
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 6
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 6
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 239000012116 Alexa Fluor 680 Substances 0.000 claims description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 210000003161 choroid Anatomy 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 33
- 208000032612 Glial tumor Diseases 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 210000004556 brain Anatomy 0.000 description 18
- 210000002307 prostate Anatomy 0.000 description 16
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 10
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 230000009870 specific binding Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 108010062745 Chloride Channels Proteins 0.000 description 6
- 102000011045 Chloride Channels Human genes 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 239000003636 conditioned culture medium Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 102000013382 Gelatinases Human genes 0.000 description 5
- 108010026132 Gelatinases Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000004624 confocal microscopy Methods 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- -1 cyanine compound Chemical class 0.000 description 5
- 230000002962 histologic effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 4
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 239000012099 Alexa Fluor family Substances 0.000 description 3
- 101100468589 Arabidopsis thaliana RH30 gene Proteins 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 229940039227 diagnostic agent Drugs 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000011503 in vivo imaging Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- IKYJCHYORFJFRR-UHFFFAOYSA-N Alexa Fluor 350 Chemical compound O=C1OC=2C=C(N)C(S(O)(=O)=O)=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O IKYJCHYORFJFRR-UHFFFAOYSA-N 0.000 description 2
- JLDSMZIBHYTPPR-UHFFFAOYSA-N Alexa Fluor 405 Chemical compound CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC.C12=C3C=4C=CC2=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C1=CC=C3C(S(=O)(=O)[O-])=CC=4OCC(=O)N(CC1)CCC1C(=O)ON1C(=O)CCC1=O JLDSMZIBHYTPPR-UHFFFAOYSA-N 0.000 description 2
- WHVNXSBKJGAXKU-UHFFFAOYSA-N Alexa Fluor 532 Chemical compound [H+].[H+].CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)N=4)(C)C)=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O WHVNXSBKJGAXKU-UHFFFAOYSA-N 0.000 description 2
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 102000003693 Hedgehog Proteins Human genes 0.000 description 2
- 108090000031 Hedgehog Proteins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000002409 gliosarcoma Diseases 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000012634 optical imaging Methods 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DOMDXTIMIZCSNC-UHFFFAOYSA-N (2Z)-2-[(2E,4E)-5-[3-[6-(2,5-dioxopyrrolidin-1-yl)oxy-6-oxohexyl]-1,1-dimethyl-6,8-disulfobenzo[e]indol-3-ium-2-yl]penta-2,4-dienylidene]-3-ethyl-1,1-dimethyl-8-sulfobenzo[e]indole-6-sulfonate Chemical compound CC1(C)C(C2=CC(=CC(=C2C=C2)S([O-])(=O)=O)S(O)(=O)=O)=C2N(CC)\C1=C/C=C/C=C/C(C(C1=C2C=C(C=C(C2=CC=C11)S(O)(=O)=O)S(O)(=O)=O)(C)C)=[N+]1CCCCCC(=O)ON1C(=O)CCC1=O DOMDXTIMIZCSNC-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012104 Alexa Fluor 500 Substances 0.000 description 1
- 239000012105 Alexa Fluor 514 Substances 0.000 description 1
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 239000012111 Alexa Fluor 610 Substances 0.000 description 1
- 239000012112 Alexa Fluor 633 Substances 0.000 description 1
- 239000012113 Alexa Fluor 635 Substances 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 239000012115 Alexa Fluor 660 Substances 0.000 description 1
- 239000012117 Alexa Fluor 700 Substances 0.000 description 1
- 239000012118 Alexa Fluor 750 Substances 0.000 description 1
- 241000984082 Amoreuxia Species 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010051635 Gastrointestinal tract adenoma Diseases 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 206010051925 Intestinal adenocarcinoma Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000239268 Leiurus quinquestriatus Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- YDIKCZBMBPOGFT-PWUSVEHZSA-N Malvidin 3-galactoside Chemical compound [Cl-].COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)=C1 YDIKCZBMBPOGFT-PWUSVEHZSA-N 0.000 description 1
- 208000035346 Margins of Excision Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100162915 Mus musculus Apex1 gene Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102000014736 Notch Human genes 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- PXUQTDZNOHRWLI-QOPOCTTISA-O Primulin Natural products O(C)c1c(O)c(OC)cc(-c2c(O[C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O3)cc3c(O)cc(O)cc3[o+]2)c1 PXUQTDZNOHRWLI-QOPOCTTISA-O 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 201000002660 colon sarcoma Diseases 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 238000012766 histopathologic analysis Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 201000009019 intestinal benign neoplasm Diseases 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000010603 microCT Methods 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
Definitions
- Matrix metalloproteinase is highly expressed in many common human malignancies including glioma, melanoma, sarcoma, breast cancer, colon adenocarcinoma, prostate cancer, neuroectodermal tumors, and ovarian cancer. MMP-2 and other MMP family members are believed to contribute to cancer invasion by proteolytic degrading adjacent non-neoplastic tissue.
- chlorotoxin is a 36 amino acid peptide that was initially characterized as a ligand that blocked reconstituted chloride channels. It was thought that CTX inhibited glioma cell migration by blocking glioma-specific chloride channels, but this activity was subsequently attributed to CTX-mediated inhibition of MMP-2. Chlorotoxin binds preferentially to glioma cells compared to normal brain. A radiopharmaceutical bound to a synthetic chlorotoxin, 131 I-TM-601, was recently approved for Phase ⁇ /IL clinical trials for brain cancer therapy based on an acceptable safety profile in preclinical studies.
- Cyanine compounds are molecular beacons that emit light in the near infrared (NIR) spectrum. Because light at this wavelength are minimally absorbed by water or hemoglobin, NIR beacons are well-suited for intra-operative imaging.
- NIR beacons are well-suited for intra-operative imaging.
- Previous attempts to image brain tumors by NIR have focused on targeting the probe to inflammatory microglia around the tumor or utilizing probes that require proteolytic cleavage for activation. The former approach is problematic because the presence of microglia correlates poorly, if at all, with margins of many brain tumors.
- dexamethasone which is a potent inhibitor of microglial activation.
- the present invention provides a chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues.
- the chlorotoxin conjugate of the invention includes one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin.
- the invention provides a fluorescent chlorotoxin conjugate having a prolonged half-life in vivo.
- the fluorescent chlorotoxin conjugate includes one or more fluorescent moieties covalently coupled to a chlorotoxin.
- the conjugate has a sufficiently long half-life to enable biophotonic imaging of cancer from about 4 to about 14 days after administration of the chlorotoxin conjugate.
- compositions that include the chlorotoxin conjugate are provided.
- the composition is suitable for administration to a human and includes pharmaceutically acceptable carrier.
- the composition includes a pharmacologically effective amount of a chlorotoxin conjugate.
- the invention provides methods for using the chlorotoxin conjugate to detect tissues of interest.
- a method for differentiating foci of cancers that express chlorotoxin binding sites from non-neoplastic tissue is provided. The method includes the steps of:
- chlorotoxin conjugate having affinity and specificity for cells that express chlorotoxin binding sites, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin;
- a method for detecting cancers that express chlorotoxin binding sites includes the steps of:
- chlorotoxin conjugate having affinity and specificity for cells that express chlorotoxin binding sites, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin;
- a method for detecting cells expressing matrix metalloproteinase (MMP-2) protein complex includes the steps of:
- chlorotoxin conjugate having affinity and specificity for matrix metalloproteinase (MMP-2) protein complex, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin; and
- a method for determining the location of cancer cells that express chlorotoxin binding sites in a patient intra-operatively is provided.
- the method includes the steps of: (a) administering a pharmaceutical composition to a patient, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and an amount of a chlorotoxin conjugate sufficient to image cancer cells that express chlorotoxin binding sites in vivo, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin;
- the invention provides methods for using the chlorotoxin conjugate to treat tissues of interest.
- the invention provides a method for treating a cancer that expresses chlorotoxin binding sites in a patient, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
- the invention provides a method for treating a cancer that expresses chlorotoxin binding sites, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
- the invention provides a method for treating a tumor expressing matrix metalloproteinase (MMP-2) protein complex, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
- MMP-2 matrix metalloproteinase
- the invention provides a method for inhibiting invasive activity of cells that express chlorotoxin binding sites, comprising administering to cells that express chlorotoxin binding sites an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
- FIGURE IA is an intra-operative photograph illustrating the clinical problem, intrinsic brain tumor tissue is often indistinguishable from normal brain tissue;
- FIGURE IB is a post-operative magnetic resonance (MR) image showing gross residual disease at sites where the glioma was intra-operatively indistinguishable from adjacent brain despite intra-operative electrophysiologic monitoring;
- MR magnetic resonance
- FIGURES 2A-2F are images illustrating biophotonic imaging of glioma;
- FIGURE 2A and 2B show a representative chlorotoxin conjugate of the invention
- CTX:Cy5.5 emits signal from every 9L glioma cell in culture (FIGURE 2A), but fails to bind fibroblasts (FIGURE 2B);
- FIGURE 2C illustrates specific binding of CTX:Cy5.5 is detected in glioma xenograft, but not otherwise normal organs of a mouse bearing a
- FIGURE 2D illustrates biophotonic images of brains from stereotaxically injected
- FIGURE 2E illustrates
- FIGURE 2D H&E stained sections from thalamus with 9L glioma invasion (top) and thalamus of uninjected control (bottom), these images correspond to the designated regions in FIGURE 2D; and FIGURE 2F illustrates the inhibition of CTX:Cy5.5 binding by the
- MMP -2 blocker 1,10-phenanthroline (left top and left bottom) compared to binding in control mice that did not receive 1,10-phenanthroline (right top and bottom);
- FIGURES 3A-3D are images illustrating detection of autochthonous medulloblastoma in genetically engineered mice;
- FIGURE 3A illustrates biophotonic images of tumor-free wild type mouse (left) and ND2:SmoAl mouse (right), mice were injected with 0.2 ml of 10 ⁇ M of a representative chlorotoxin conjugate of the invention (CTX:Cy5.5) 1.5 days prior to imaging;
- FIGURE 3B illustrates images of brains from the same mice following necropsy;
- FIGURE 3 C illustrates histologic confirmation of medulloblastoma (right) compared to normal cerebellum (left);
- FIGUEE 3D illustrates confocal microscopy images from the same brains shown in FIGURE 3B demonstrating near absence of Cy5.5 signal in control (left) and high signal in medulloblastoma (right);
- FIGURES 4A-4E are images illustrating the specificity of a representative chlorotoxin conjugate of the invention
- FIGURES 5A-5F illustrate imaging of adenocarcinomas and sarcomas with a representative chlorotoxin conjugate of the invention (CTX:Cy5.5);
- FIGURE 5A is an H&E stained section of adenocarcinoma shown in FIGURE 5B;
- FIGURE 5B illustrates biophotonic images of adenocarcinoma (left) and adenoma (right) showing clear delineation from normal intestine;
- FIGURE 5 C illustrates histologic confirmation of adenoma shown in FIGURE 5B;
- FIGURE 5D illustrates NIR images of RH30 rhabdomyosarcoma xenograft from mouse that was not injected with CTX:Cy5.5 (top) and a mouse that received 0.2 ml of 10 ⁇ M CTX:Cy5.5 1.5 days prior to imaging;
- FIGURE 5E illustrates confocal images of the corresponding tumors from mice that were uninjected (left) and injected (right);
- CTX:Cy5.5 representative chlorotoxin fluorophore conjugate of the invention
- FIGURES 7A- 7E illustrates a comparison of three fluorophores conjugated to chlorotoxin;
- FIGURE 7A shows no tumor-specific signal is seen with CTX:fluorescein in mice bearing 9L gliomas within the first hour after imaging;
- FIGURE 7B illustrates a mouse on the left was injected with CTX:fluorescein directly into the tumor to demonstrate that the conjugate was emitting and being detected properly;
- FIGURE 7C illustrates a mouse with 9L glioma imaged within 1 hour after injection of CTX: ALEXA- 680 showing signal in tumor;
- FIGURE 7D is an image 24 hours after injection, excellent signal is observed from CTX:Cy5.5 in tumor compared to opposite non-neoplastic flank (the signal above the tumor is from kidney excretion of bioconjugate), a weaker signal from tumor is seen in ALEXA-680 treated mouse #2, but not #1, reinjection of mouse #1 resulted in rapid clearance of conjugate from non-neoplastic and tumor
- FIGURES 9A and 9B illustrate HPTLC of phospholipid standards and lipids isolated from various cell lines as indicated;
- FIGURE 9A is an image of a HPTLC plate was developed in chloroform:methanol: water (65:25:4) and lipids were visualized with the lipophilic dye, stimulin;
- FIGURE 9B is an image pf a HPTLC overlay of lipids with IuM CTX:Cy5.5; abbreviations: PS, phosphatidylserine; PI, phosphatidylinositol: PG, phosphatidylglycerol; PE, phosphatidylethanolamine; PIP2, phosphatidylinositol 4,5-bisphosphate; PC, phosphatidylcholine; SM, sphingomyelin;
- FIGURES 10A-10E illustrate specific CTX:Cy5.5 binding in brain tumors compared to normal brain on histologic sections;
- FIGURE 1OA hematoxylin and eosin (H&E) stained section of glioma;
- FIGURE 1OB CTX:Cy5.5 staining of same glioma;
- FIGURE 1OC Cy5.5 alone does not stain glioma;
- FIGURE 10D H&E stained section of normal brain from same patient;
- FIGURE 1OE CTX:Cy5.5 does not stain normal brain;
- FIGURE 11 illustrates MMP-2 and MMP-9 activity in mouse tumors and normal tissue; gelatinase assays were conducted to evaluate MMP-2 expression in the tissues listed above; MMP-2 activity was detected in all cancer foci that were detected by CTX:Cy5.5, but not corresponding non-neoplastic tissue; and MMP-9 activity was detected in mouse medulloblastoma tumors (SmoAl) and prostate tumor, but not
- FIGURE 12 illustrates MMP-2 and MMP-9 activity in cell lines and media from cell lines. Top: gelatinase activity in cells separated from media shows very little MMP-2 activity in 9L cells and much more activity in U87 cells despite the fact that 9L cells bind CTX:Cy5.5 as well as U87cells.
- FIGURES 13A-13F illustrate CTX:Cy5.5 in media from cells with high levels of secreted MMP-2 and MMP-9 stains cells that are negative for CTX:Cy5.5 staining alone;
- FIGURE 13A shows MCF-7 cells incubated with CTX:Cy5.5 fail to emit in the near infrared (Cy5.5) spectrum (red), nuclei are stained blue with DAPI;
- FIGURE 13B shows a sister plate of MCF-7 cells incubated with the same amount of CTX:Cy5.5 as in FIGURE 13A, except this CTX:Cy5.5 was transferred in media after 24 hour exposure to 9L glioma cells (CTX:Cy5.5 stains MCF-7 cells under this condition);
- FIGURE 13C shows a sister plate of MCF-7 cells stained with CTX:Cy5.5
- the present invention provides a chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues, compositions that include the chlorotoxin conjugate, and methods for using the chlorotoxin conjugate.
- the present invention provides a chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues.
- the chlorotoxin is a targeting agent that directs the conjugate to a tissue of interest.
- the chlorotoxin conjugate of the invention includes one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin.
- the chlorotoxin may be native chlorotoxin, synthetic chlorotoxin, or recombinant chlorotoxin. Chlorotoxin fragments and variants having chlorotoxin binding activity (e.g., specificity and affinity to cancerous tissues) may also be used.
- red or near infrared emitting fluorescent moiety refers to a fluorescent moiety having a fluorescence emission maximum greater than about 600 nm.
- Fluorescent chlorotoxin conjugates having shorter wavelength (e.g., from about 500 to about 600 nm) emitting fluorescent moieties are useful in histochemical imaging. These conjugates may be useful less for in vivo imaging in humans and animals where longer wavelength (e.g., greater than about 600 nm) emitting fluorescent moieties are preferred.
- the fluorescent moieties are derived from fluorescent compounds characterized by emission wavelength maxima greater than about 600 run to avoid autofluorescence, emission that travels through millimeters to one centimeter of tissue/blood/fluids, emission that is not absorbed by hemoglobin, other blood components, or proteins in human or animal tissue.
- the fluorescent moiety is covalently coupled to the chlorotoxin to allow for the visualization of the conjugate by fluorescence imaging.
- the fluorescent moiety is derived from a fluorescent compound. Suitable fluorescent compounds are those that can be covalently coupled to a chlorotoxin without substantially adversely affecting the targeting and binding function of the chlorotoxin conjugate. Similarly, suitable fluorescent compounds retain their fluorescent properties after conjugation to the chlorotoxin.
- the fluorescent moiety is a cyanine moiety.
- Cyanine compounds are characterized by their relative high extinction coefficients and favorable fluorescence quantum yields.
- the fluorescence emission wavelength maximum for a cyanine compound varies as a function of the cyanine structure. Depending on the particular cyanine compound, the fluorescence emission wavelength maxima can vary from the green (about 490 nm) to the near infrared (about 740 nm).
- cyanine compounds having fluorescence emission maxima in the far red (about 650 nm) to the near infrared (about 750 nm) are preferred. At these emission wavelengths, background fluorescence from the local environment is minimal and tissues of interest are relatively transparent.
- excitation and fluorescence emission visualization is maximized and relatively greater amounts of tissue targeted by the conjugate of the invention can be observed compared to other conjugates utilizing fluorescent compounds having emission at shorter wavelengths (less than 600 nm).
- Suitable cyanines include the CYDYE fluors commercially available from GE Healthcare under the designation Cy2 (506 nm); Cy2 (506 nm); Cy3 (570 nm); Cy3B (572 nm); Cy3.5 (596 nm); Cy5 (670 nm); Cy5.5 (675 nm); and Cy7 (694 nm) (emission maxima in parentheses).
- the cyanine compound is Cy5.5.
- the preparation of a representative cyanine-chlorotoxin conjugate is described in Example 1.
- the fluorescent moiety is a sulfonated xanthene moiety.
- Sulfonated xanthene compounds suitable for use in the practice of the invention are described in U.S. Patent No. 6,130,101, expressly incorporated herein by reference in its entirety, and commercially available under the designation ALEXA FLUOR from Molecular Probes, Inc., Eugene, OR.
- ALEXA FLUOR is the designation for a family of fluorophores that are characterized by their relative high extinction coefficients and favorable fluorescence quantum yields. The fluorescence emission wavelength maximum for a sulfonated xanthene compound varies as a function of the compound's structure.
- the fluorescence emission wavelength maxima can vary from the green (about 450 nm) to the near infrared (about 780 nm).
- ALEXA FLUOR compounds having fluorescence emission maxima in the far red (about 650 nm) to the near infrared (about 750 nm) are preferred.
- Suitable sulfonated xanthene compounds include ALEXA FLUORS, such as ALEXA FLUOR 350 (442 nm), ALEXA FLUOR 405 (421 nm), ALEXA FLUOR 488 (539 nm), ALEXA FLUOR 500 (525 nm), ALEXA FLUOR 514 (540 nm), ALEXA FLUOR 532 (554 nm), ALEXA FLUOR 546 (575 nm), ALEXA FLUOR 555 (565 nm), ALEXA FLUOR 568 (603 nm), ALEXA FLUOR 594 (617 nm), ALEXA FLUOR 610 (628 nm), ALEXA FLUOR 633 (647 nm), ALEXA FLUOR 635 (645 nm), ALEXA FLUOR 647 (668 nm), ALEXA FLUOR 660 (690 nm), ALEXA FLU
- the sulfonated xanthene is ALEXA FLUOR 680.
- Representative sulfonated xanthene-chlorotoxin conjugates can be prepared in manner analogous to that described for cyanine conjugation in Example 1 and as further described in The Handbook - A Guide to Fluorescent Probes and Labeling Technologies, Richard P. Haugland (Molecular Probes, Inc., a subsidiary of Invitrogen Corp.).
- Suitable fluorescent compounds include a functional group that renders the compound chemically reactive toward the chlorotoxin.
- Suitable functional groups include the N-hydroxysuccinimide (NHS) group for covalent coupling to amine groups, the maleimide group for covalent coupling to thiol groups, and the hydrazide group for covalent coupling to aldehyde groups.
- the fluorescent compound useful in preparing the conjugate of the invention includes a single reactive functional group (e.g., mono-NHS ester). It will be appreciated that other conjugating chemistries are suitable for making the chlorotoxin conjugate of the present invention.
- Suitable conjugates of the invention include from about 1 to about 3 fluorescent moieties/chlorotoxin. In one embodiment, the conjugate include about 1 fluorescent moiety.
- Example 1 The preparation of a representative chlorotoxin conjugate of the invention is described in Example 1.
- hi vitro imaging using a representative chlorotoxin conjugate of the invention is described in Example 2.
- hi vivo imaging using a representative chlorotoxin conjugate of the invention is described in Example 3.
- the invention provides a fluorescent chlorotoxin conjugate having a prolonged half-life in vivo.
- the fluorescent chlorotoxin conjugate includes one or more fluorescent moieties covalently coupled to a chlorotoxin.
- the conjugate has a sufficiently long half-life to enable biophotonic imaging of cancer from about 4 to about 14 days after administration of the chlorotoxin conjugate.
- compositions that include the chlorotoxin conjugate are provided.
- the composition is suitable for administration to a human and animal subjects and includes pharmaceutically acceptable carrier.
- the composition includes a pharmacologically effective amount of a chlorotoxin conjugate.
- An effective amount can be routinely determined by established procedures.
- An effective amount is an amount sufficient to occupy chlorotoxin binding sites in cancer cells, but low enough to minimize non-specific binding to non-neoplastic tissues.
- An effective amount optimizes signal-to-noise ratio for intra-operative imaging.
- the invention provides methods for using the chlorotoxin conjugate to detect and treat tissues of interest.
- the invention provides methods for detecting a tissue using the chlorotoxin conjugates.
- the chlorotoxin conjugates of the invention target and are bound by chlorotoxin binding sites. It will be appreciated that chlorotoxin binding sites may take two forms: sites that bind chlorotoxin and sites that bind the chlorotoxin conjugates of the invention. It will be appreciated that chlorotoxin binding sites may be distinct from chlorotoxin conjugate binding sites.
- a method for differentiating foci of cancers that express chlorotoxin binding sites from non-neoplastic tissue is provided.
- the method includes the steps of: (a) contacting a tissue of interest with a chlorotoxin conjugate having affinity and specificity for cells that express chlorotoxin binding sites, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin; and (b) measuring the level of binding of the chlorotoxin conjugate, wherein an elevated level of binding, relative to normal tissue, is indicative that the tissue is neoplastic.
- a method for detecting cancers that express chlorotoxin binding sites includes the steps of: (a) contacting a tissue of interest with a chlorotoxin conjugate having affinity and specificity for cells that express chlorotoxin binding sites, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin; and
- a method for detecting cells expressing matrix metalloproteinase (MMP-2) protein complex includes the steps of: (a) contacting a tissue of interest with a chlorotoxin conjugate having affinity and specificity for matrix metalloproteinase (MMP-2) protein complex, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin; and
- MMP-2 matrix metalloproteinase
- a method for determining the location of cancer cells that express chlorotoxin binding sites in a patient intra-operatively includes the steps of:
- the imaging methods of the invention for detection of cancer foci is applicable to mouse and other animal models of cancer as well as to veterinary practice.
- the invention provides methods for treating a tissue using the chlorotoxin conjugates.
- the invention provides a method for treating a cancer that expresses chlorotoxin binding sites in a patient, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
- the invention provides a method for treating a cancer that expresses chlorotoxin binding sites, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
- the invention provides a method for treating a tumor expressing matrix metalloproteinase (MMP-2) protein complex, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
- MMP-2 matrix metalloproteinase
- the invention provides a method for inhibiting invasive activity of cells that express chlorotoxin binding sites, comprising administering to cells that express chlorotoxin binding sites an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
- the methods of treatment of the invention are applicable to human and animal subjects in need of such treatment.
- the chlorotoxin conjugates of the invention can be used to detect and treat various cancers (e.g., prostate cancer, sarcomas, hematological malignancies, and leukemias) and various neuroectodermal tumors (e.g., glioma, meningioma, ependymonas, medulloblastoma, neuroblastoma, glioblastoma, ganglioma, pheochromocytoma, melanoma, Ewing's sarcoma, small cell lung carcinoma, and metastatic brain tumors).
- cancers e.g., prostate cancer, sarcomas, hematological malignancies, and leukemias
- various neuroectodermal tumors e.g., glioma, meningioma, ependymonas, medulloblastoma, neuroblastoma, glioblastoma, gan
- MMP-2 expression is expected to specifically bind the chlorotoxin conjugates of the invention (e.g., CTX:Cy5.5).
- malignant cancers include gliomas, astrocytomas medulloblastomas, choroids plexus carcinomas, ependymomas, other brain tumors, neuroblastoma, head and neck cancer, lung cancer, breast cancer, intestinal cancer, pancreatic cancer, liver cancer, kidney cancer, sarcomas (over 30 types), osteosarcoma, rhabdomyosarcoma, Ewing's sarcoma, carcinomas, melanomas, ovarian cancer, cervical cancer, lymphoma, thyroid cancer, anal cancer, colo-rectal cancer, endometrial cancer, germ cell tumors, laryngeal cancer, multiple myeloma, prostate cancer, retinoblastoma, gastric cancer, testicular cancer, and Wilm's tumor.
- the fluorescent chlorotoxin conjugate of the invention may include other useful agents.
- Other useful agents include diagnostic agents and therapeutic agents.
- Suitable diagnostic agents include agents that provide for the detection of the nanoparticle by methods other than fluorescence imaging.
- Other suitable diagnostic agents include radiolabels (e.g., radio isotopically labeled compounds) such as 125 I, 4 C, and 31 P, among others.
- Suitable therapeutic agents include cytotoxic agents.
- Representative therapeutic agents include chemotherapeutic agents such as methotrexate, docetaxel, cisplatin, and etoposide, among others.
- Other therapeutic agents include nucleic acid molecules (e.g., DNAs and RNAs, such as siRNAs) for specific cancers and diseases.
- the present invention provides a chlorotoxin conjugate (e.g., CTX:Cy5.5) that enables real time biophotonic imaging of malignant cancer foci as small as 1.5 mm.
- a chlorotoxin conjugate e.g., CTX:Cy5.5
- CTX:Cy5.5 chlorotoxin conjugate
- the same agent clearly delineated malignant prostate cancer cells from normal prostate at single cell resolution in human surgical biopsy samples, establishing the relevance of the mouse studies to human disease. See Examples 2 and 3. All tissues sent to pathology tagged as cancer based on CTX:Cy5.5 signal were cancerous and all adjacent normal tissues were histologically normal. The resolution of cancer foci from normal tissue under simulated operating conditions wasaki.
- CTX Chlorotoxin
- Chlorotoxin was originally thought to bind to a chloride channel and early studies indicated that it impaired transmembrane chloride flux.
- the use of a chloride channel toxin that crosses the blood brain barrier would obviously be problematic for clinical application of CTX-based probes.
- Recent work has determined that chlorotoxin does not bind to chloride ion channels and that the original report was scientifically flawed.
- specific binding of CTX:Cy5.5 to non-neoplastic brain tissue was minimal.
- no neurologic or behavioral deficits and no neuropathology in brains of mice that had been exposed to CTX:Cy5.5 were observed. This is consistent with the absence of neurotoxicity in other studies, including one that involved direct injection of CTX into mouse brain.
- the chlorotoxin conjugate of the invention enables detection and monitoring of a variety of cancers in mouse models.
- This approach adds particular value to genetically engineered mouse (GEM) models of human cancers, which in contrast to xenograft or mutagenic models of cancer, develop in situ cancers as a result of genetic manipulation that recapitulates human disease.
- GEM mice A particular advantage of GEM mice is that tumors can be studied from early to advanced stages to better understand the evolution of growth, angiogenesis, local invasion, metastases, drug response and drug resistance.
- the present invention provides a chlorotoxin conjugate (e.g., CTX:Cy5.5, a representative chlorotoxin conjugate of the invention) that enabled real-time biophotonic imaging of xenografted gliomas and sarcomas.
- the chlorotoxin conjugate also effectively distinguished autochthanous medulloblastoma, prostate, and intestinal cancers from normal tissues in genetically engineered mice (GEM). Micrometastases to lung and lymph nodes were readily detected. Human tumor specimens showed perfect correlation between CTX:Cy5.5 binding and rests of prostate cancer cells.
- a representative chlorotoxin conjugate of the invention, CTX:Cy5.5 was prepared by conjugating Cy5.5 to chlorotoxin.
- the conjugate was synthesized using a mixture of CTX (Alomone Labs, Israel, 250 ul of 2 mg/ml in 50 mM bicarbonate buffer, pH 8.5) and Cy5.5-NHS ester (Amersham Biosciences, Sweden, 43 ul of 10 mg/ml in anhydrous dimethylformamide). Conjugation was performed in dark at room temperature for 1 hour. Unconjugated dye was removed by dialysis against PBS (3 times) using Slide- A-Lyzer (Pierce Biotechnology, IL) membrane (Mr 3 cutoff, 3500) for 9 hours at 4 0 C. Samples were diluted with PBS to produce 1 and 10 uM of CTX solution and filtered with a 0.2 um syringe filter before use.
- CTX bicinchoninic acid
- 9L/lacZ gliosarcoma cells ATCC, VA
- HFF primary human foreskin fibroblast
- DAPI 4',6-diamidino-2-phenyindole
- ND2:SmoAl medulloblastoma mice, TRAMP prostate cancer mice and Apc y ⁇ J5lW intestinal adenoma and adenocarcinoma mice were as previously described. See, Fodde, R., et al., A targeted chain-termination mutation in the mouse Ape gene results in multiple intestinal tumors. Proc. Natl. Acad. ScL U.S.A., 1994. 91(19): p. 8969-73; Greenberg, N.M., et al., Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. U.S.A., 1995. 92(8): p.
- Biophotonic images were obtained on the Xenogen IVIS system (Alameda, CA). Mice were anesthetized with 1 to 2.5% isoflurane (Abbott Labs, IL) before they were placed in the imaging chamber and imaged at various time points postinjection. Relevant organs and tumors were dissected from some of the animals and fluorescence image were obtained immediately following dissection. In time course experiments, all images were captured using identical system settings and fluorescence emission was normalized to photons per second per centimeter squared per steradian (p/s/cm 2 /sr). All experiments were repeated multiple times and representative images are shown in the figures.
- Non-invasive imaging of medulloblastoma through cranial bone CTX:Cy5.5 was tested in a genetically precise autochthonous mouse model of medulloblastoma. In these mice, medulloblastomas arise in the cerebellum due to transgenic expression of constitutively active smoothened, a mediator of sonic hedgehog activity. In these mice, tumors were detected through intact skull and scalp and the level of NIR emission correlated with the size of each tumor (FIGURES 3A-D and not shown).
- CTX:Cy5.5 enters mouse medulloblastoma tissue at concentrations suitable for real time imaging and that intracranial tumors can be readily detected noninvasively.
- Prostate tissue imaging Normal and cancerous human prostate tissue samples were collected and handled in accordance with Human Subjects HRB approved protocols. Sections were incubated with 1 ⁇ M CTX:Cy5.5 conjugate in 5% normal goat serum buffer for 45 minutes. Unbound conjugate was reduced by washing slides 3 times for 5minutes in PBS buffer. Signal was detected by fluorescence microscopy and correlated to adjacent sections stained with hematoxylin and eosin (H&E).
- CTX:Cy5.5 binding to sections of surgically-derived human prostate cancer was compared to non-neoplastic prostate epithelium. No specific binding was observed in normal prostate tissue, whereas high levels of CTX:Cy5.5 were observed in islands of cancer cells (FIGURE 4A). Adjacent sections revealed perfect correlation between rests of cancer cells detected by CTX:Cy5.5 and standard histologic staining (FIGURE 4A).
- CTX:Cy5.5 binding to human prostate cancer sections lead to evaluation of the conjugate in a GEM model of prostate cancer.
- CTX:Cy5.5 illuminated the primary prostate cancer as well as lung and lymphatic metastases (FIGURES 4B-D).
- CTX:Cy5.5 binding correlated with the histological presence of neoplastic cells in the primary and distant organs (FIGURE 4C). Microscopic foci of cancer cells in lymphatic channels and lymph nodes were easily detected (FIGURES 4D-E).
- CTX:Cy5.5 binding in adenocarcinoma and sarcoma was evaluated.
- FAP familial adenomatous polyposis
- Apc 1638N mice intestinal neoplasms could not be resolved by noninvasive imaging because of autofluorescence of the intestinal contents.
- Ex vivo analysis of intestine that was free of intestinal contents showed extremely delineation of 3-5 mm diameter cancer nodules and no appreciable signal from otherwise normal intestine (FIGURES 5A-C).
- Microscopic analyses of the rhabdomyosarcoma xenograft showed that virtually every cancer cell was brightly illuminated by CTX:Cy5.5 (FIGURES 5D-F).
- CTX and Cy5.5 have previously been administered to human patients in clinical trials, but the pharmacokinetic properties of the conjugate have not previously been studied. Unbound conjugates were fairly evenly distributed through the mouse body during the first 24-96 hours, with the exception that NIR emission from kidney was much higher than any other organ. Confocal microscopy showed that CTX:Cy5.5 was concentrated in the renal collecting system as expected for a compound that is primarily excreted in urine. No other organ showed specific binding of CTX:Cy5.5.
- CTX was previously reported to reduce locomotor activity in mice. In this study, mice that were injected with CTX were indistinguishable from control mice in open field observation. To further assess potential CTX toxicity at doses used for optical imaging, complete necropsy was performed on mice two weeks after exposure to CTX. Brain, heart, lungs, kidneys, liver, spleen, and skin were indistinguishable from control mice
- MMP-2 The involvement of MMP-2 in chlorotoxin conjugate binding is described in this example.
- CTX:Cy5.5 was observed in mouse medulloblastoma tumors and human medulloblastoma histologic sections. This raised the possibility that MMP-2 was not the target of CTX:Cy5.5, despite a previously published report that CTX binds to MMP-2.
- MMP-2 activity was analyzed by gelatinase assays. Gelatinase assays also detect MMP-9 activity. These analyses showed that all tumors that bound CTX:Cy5.5 express MMP-2 and MMP-9 and that autochthanous tumors in genetically engineered medulloblastoma and prostate cancer models also express MMP-2, but not MMP-9 (see FIGURE 11). Non-neoplastic tissue from mice did not show MMP-2 or MMP-9 activity. This experiment showed that MMP-2 was expressed in tissues that bound CTX:Cy5.5, but not in non-neoplastic tissues that showed only background CTX:Cy5.5 binding.
- MMP-2 reduced CTX:Cy5.5 binding in vitro and in vivo experiments suggesting that MMP-2 may be important for CTX:Cy5.5 binding (see FIGURE 2F and not shown).
- FIGURE 2F To further, definitively, determine whether MMP-2 was involved in CTX:Cy5.5 binding, a genetic approach was taken.
- MCF-7 cells which minimally express MMP-2 and minimally bind CTX:Cy5.5 (see FIGURES 11 and 8) were transfected with a plasmid that encodes MMP-2. Following transfection, cells expressed high levels of MMP-2 as shown in green in FIGURE 8.
- MCF-7 cells transfected with MMP-2 plasmid but not those transfected with control plasmid bound high levels of CTX:Cy5.5 and this signal highly localized with MMP-2 staining. This clearly demonstrates that MMP-2 is important for CTX:Cy5.5 binding.
- CTX:Cy5.5 binding to cells than the intracellular form was compared under the following three conditions.
- Condition (1) CTX:Cy5.5 was added directly to MCF7 or HeLa media and incubated for 24 hours under conditions that resulted in high CTX:Cy5.5 binding to 9L or U87 cells. There was minimal staining of MCF7 or HeLa cells under these conditions, hi Condition (2) the same amount of CTX:Cy5.5 was added to media of 9L or U87 cells, incubated for 24 hours, then transferred to MCF7 or HeLa cells.
- CTX:Cy5.5 When conditioned media from either 9L or U87 cells was used for staining, both MCF7 and HeLa cells were brightly stained by CTX:Cy5.5 (see FIGURE 13). Because the amount of MMP2 does not change in MCF7 or HeLa cells due to the presence of conditioned media, CTX:Cy5.5 ultimately binds to a target other than MMP-2. There are two major possibilities that are currently being studied: (1) MMP-2 enzymatically alters CTX:Cy5.5 so that it gains affinity for another cellular target; or (2) MMP-2 enzymatically alters molecule(s) in MCF7 or HeLa cells so that they gain affinity for CTX:Cy5.5.
- MMP-2 was shown as important for CTX:Cy5.5 binding, but that it may not be the ultimate cellular target of CTX:Cy5.5.
- CTX:Cy5.5 wa observed to bind to a rapidly migrating band on Western analyses that was consistent with a phospholipid band. This raised the possibility that CTX:Cy5.5 bound to a phospholipid.
- Sphingomyelin and phosphatidylcholine are present in all cells and only a subset of MCF7 and HeLa cells treated with CTX:Cy5.5 conditioned media from 9L and U87 cells showed high levels of signal.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Abstract
A chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues, compositions that include the chlorotoxin conjugate, and methods for using the chlorotoxin conjugate.
Description
FLUORESCENT CHLOROTOXIN CONJUGATE AND METHOD FOR INTRAOPERATIVE VISUALIZATION OF CANCER
STATEMENT OF GOVERNMENT LICENSE RIGHTS This invention was made with government support under Grant
Nos. NOl C037007-16, CA84296, and CA97186 awarded by the National Institutes of Health. The government has certain rights in the invention.
BACKGROUND OF THE INVENTION For many types of cancer, the precision of surgical resection directly influences patient prognosis. Unfortunately, intra-operative identification of tumor margins or small foci of cancer cells remains imprecise or depends on surgical judgment. Thus, the extent of surgical resection is constrained by the requirement to avoid harming vital structures. Nowhere is this more problematic than in the brain, where greater than 80% of malignant cancers recur at the surgical margin. Despite advances in intra-operative monitoring and image guidance, post-operative scans sometimes reveal bulky residual tumor that may have been resected if the surgeon had improved tools to distinguish tumor tissue from normal brain. Recent advances in molecular biology, genomics and proteomics have yielded information about molecules that are expressed in malignant cells but not adjacent tissue. This information has the potential to fundamentally transform surgical oncology if used to specifically "paint" tumor cells with targeted molecular beacons.
Matrix metalloproteinase (MMP-2) is highly expressed in many common human malignancies including glioma, melanoma, sarcoma, breast cancer, colon adenocarcinoma, prostate cancer, neuroectodermal tumors, and ovarian cancer. MMP-2 and other MMP family members are believed to contribute to cancer invasion by proteolytic degrading adjacent non-neoplastic tissue.
Isolated from the scorpion Leiurus quinquestriatus, chlorotoxin (CTX) is a 36 amino acid peptide that was initially characterized as a ligand that blocked reconstituted chloride channels. It was thought that CTX inhibited glioma cell migration by blocking glioma-specific chloride channels, but this activity was subsequently attributed to CTX-mediated inhibition of MMP-2. Chlorotoxin binds preferentially to glioma cells compared to normal brain. A radiopharmaceutical bound to a synthetic chlorotoxin, 131I-TM-601, was recently approved for Phase Ϊ/IL clinical trials for brain cancer therapy based on an acceptable safety profile in preclinical studies.
Cyanine compounds are molecular beacons that emit light in the near infrared (NIR) spectrum. Because light at this wavelength are minimally absorbed by water or hemoglobin, NIR beacons are well-suited for intra-operative imaging. Previous attempts to image brain tumors by NIR have focused on targeting the probe to inflammatory microglia around the tumor or utilizing probes that require proteolytic cleavage for activation. The former approach is problematic because the presence of microglia correlates poorly, if at all, with margins of many brain tumors. Furthermore, to reduce perioperative brain edema, patients are treated with dexamethasone which is a potent inhibitor of microglial activation. Despite the advances in the development of probes for targeting and imaging brain tumors and in view of the factors noted above, there exists a need for a probe that does not require enzymatic cleavage and that allows for intra-operative visualization of cancerous tissues. The present invention seeks to fulfill this need and provides further related advantages. SUMMARY OF THE INVENTION
In one aspect, the present invention provides a chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues. In one embodiment, the chlorotoxin conjugate of the invention includes one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin.
In another embodiment, the invention provides a fluorescent chlorotoxin conjugate having a prolonged half-life in vivo. The fluorescent chlorotoxin conjugate includes one or more fluorescent moieties covalently coupled to a chlorotoxin. In one embodiment, the conjugate has a sufficiently long half-life to enable biophotonic imaging of cancer from about 4 to about 14 days after administration of the chlorotoxin conjugate. In another aspect of the invention, compositions that include the chlorotoxin conjugate are provided. The composition is suitable for administration to a human and includes pharmaceutically acceptable carrier. The composition includes a pharmacologically effective amount of a chlorotoxin conjugate. In another aspect, the invention provides methods for using the chlorotoxin conjugate to detect tissues of interest.
In one embodiment, a method for differentiating foci of cancers that express chlorotoxin binding sites from non-neoplastic tissue is provided. The method includes the steps of:
(a) contacting a tissue of interest with a chlorotoxin conjugate having affinity and specificity for cells that express chlorotoxin binding sites, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin; and
(b) measuring the level of binding of the chlorotoxin conjugate, wherein an elevated level of binding, relative to normal tissue, is indicative that the tissue is neoplastic.
In one embodiment, a method for detecting cancers that express chlorotoxin binding sites is provided. The method includes the steps of:
(a) contacting a tissue of interest with a chlorotoxin conjugate having affinity and specificity for cells that express chlorotoxin binding sites, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin; and
(b) measuring the level of binding of the chlorotoxin conjugate, wherein an elevated level of binding, relative to normal tissue, is indicative that the tissue is neoplastic. In one embodiment, a method for detecting cells expressing matrix metalloproteinase (MMP-2) protein complex is provided. The method includes the steps of:
(a) contacting a tissue of interest with a chlorotoxin conjugate having affinity and specificity for matrix metalloproteinase (MMP-2) protein complex, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin; and
(b) measuring the level of binding of the chlorotoxin conjugate, wherein an elevated level of binding, relative to normal tissue, is indicative of the presence of a tumor expressing matrix metalloproteinase (MMP-2) protein complex. In one embodiment, a method for determining the location of cancer cells that express chlorotoxin binding sites in a patient intra-operatively is provided. The method includes the steps of:
(a) administering a pharmaceutical composition to a patient, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and an amount of a chlorotoxin conjugate sufficient to image cancer cells that express chlorotoxin binding sites in vivo, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin;
(b) measuring the level of binding of the chlorotoxin conjugate by fluorescence imaging to determine the location of cancer cells that express chlorotoxin binding sites, wherein an elevated level of binding, relative to normal tissue, is indicative of the presence of cancer cells that express chlorotoxin binding sites; and
(c) surgically removing from the patient at least some cells that express chlorotoxin binding sites located by fluorescence imaging.
In another aspect, the invention provides methods for using the chlorotoxin conjugate to treat tissues of interest. In one embodiment, the invention provides a method for treating a cancer that expresses chlorotoxin binding sites in a patient, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
In one embodiment, the invention provides a method for treating a cancer that expresses chlorotoxin binding sites, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
In one embodiment, the invention provides a method for treating a tumor expressing matrix metalloproteinase (MMP-2) protein complex, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
In one embodiment, the invention provides a method for inhibiting invasive activity of cells that express chlorotoxin binding sites, comprising administering to cells that express chlorotoxin binding sites an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
Methods for making the chlorotoxin conjugates are also provided.
DESCRIPTION OF THE DRAWINGS
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee. The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:
FIGURE IA is an intra-operative photograph illustrating the clinical problem, intrinsic brain tumor tissue is often indistinguishable from normal brain tissue;
FIGURE IB is a post-operative magnetic resonance (MR) image showing gross residual disease at sites where the glioma was intra-operatively indistinguishable from adjacent brain despite intra-operative electrophysiologic monitoring;
FIGURES 2A-2F are images illustrating biophotonic imaging of glioma; FIGURE 2A and 2B show a representative chlorotoxin conjugate of the invention
(CTX:Cy5.5) emits signal from every 9L glioma cell in culture (FIGURE 2A), but fails to bind fibroblasts (FIGURE 2B); FIGURE 2C illustrates specific binding of CTX:Cy5.5 is detected in glioma xenograft, but not otherwise normal organs of a mouse bearing a
9L glioma xenograft 32 days after systemic administration of 0.2 ml of 10 μM conjugate; FIGURE 2D illustrates biophotonic images of brains from stereotaxically injected
9L glioma (top), sham surgery control (middle), and no surgery control (bottom) animals taken 1.5 days after administration of 0.2 ml of 10 μM conjugate; FIGURE 2E illustrates
H&E stained sections from thalamus with 9L glioma invasion (top) and thalamus of uninjected control (bottom), these images correspond to the designated regions in FIGURE 2D; and FIGURE 2F illustrates the inhibition of CTX:Cy5.5 binding by the
MMP -2 blocker, 1,10-phenanthroline (left top and left bottom) compared to binding in control mice that did not receive 1,10-phenanthroline (right top and bottom);
FIGURES 3A-3D are images illustrating detection of autochthonous medulloblastoma in genetically engineered mice; FIGURE 3A illustrates biophotonic images of tumor-free wild type mouse (left) and ND2:SmoAl mouse (right), mice were injected with 0.2 ml of 10 μM of a representative chlorotoxin conjugate of the invention (CTX:Cy5.5) 1.5 days prior to imaging; FIGURE 3B illustrates images of brains from the same mice following necropsy; FIGURE 3 C illustrates histologic confirmation of
medulloblastoma (right) compared to normal cerebellum (left); and FIGUEE 3D illustrates confocal microscopy images from the same brains shown in FIGURE 3B demonstrating near absence of Cy5.5 signal in control (left) and high signal in medulloblastoma (right); FIGURES 4A-4E are images illustrating the specificity of a representative chlorotoxin conjugate of the invention (CTX:Cy5.5) for human and mouse prostate cancer; FIGURE 4A illustrates fluorescent images of Cy5.5 signal (red) in foci of prostate cancer (CAP) adjacent to normal prostate (NP, green autofluorescence) in human surgical specimens (1st and 3rd panels), the 5th panel is normal prostate, showing no Cy5.5 signal, corresponding H&E stained adjacent sections are shown to the right of each NIR image; FIGURE 4B illustrates biophotonic images of prostate and other organs from TRAMP mouse (top panel) and wild type control (bottom panel) showing specific signal in TRAMP prostate (CAP) and lung (red arrow), images were obtained 5.5 days after injection of 0.1 ml of 10 μM conjugate, top row organs: brain, heart, kidney, liver, lung, spleen, and lower row: prostate; FIGURE 4C illustrates confocal microscopy sections from the same prostate samples shown in FIGURE 4B, high CTX:Cy5.5 binding was present in nearly every cell of the prostate cancer (top left) and was minimal in normal prostate (bottom left), H&E stained adjacent sections (center) show lung metastases in the TRAMP mouse lung (upper right) that is bright in FIGURE 4B and normal lung from the control mouse (lower right); and FIGURE 4D illustrates intra-operative images of control (left) and TRAMP (right) mouse abdomen following removal of intestine, prostate, and liver, multiple lymph nodes (N) were positive by biophotonic imaging and histology, a 1.5 mm diameter tissue nodule that was very bright on imaging revealed three small foci of prostate cancer cells in lymph channels surrounded by fat and reactive tissue (L), lower amounts of signal were detected in fat (F) and testes (T); FIGURE 4E illustrates hematoxylin and eosin stained section showing a small focus of cancer cells in a lymph channel (labeled L in FIGURE 4D) and cancer-containing lymph node;
FIGURES 5A-5F illustrate imaging of adenocarcinomas and sarcomas with a representative chlorotoxin conjugate of the invention (CTX:Cy5.5); FIGURE 5A is an H&E stained section of adenocarcinoma shown in FIGURE 5B; FIGURE 5B illustrates biophotonic images of adenocarcinoma (left) and adenoma (right) showing clear delineation from normal intestine; FIGURE 5 C illustrates histologic confirmation of adenoma shown in FIGURE 5B; FIGURE 5D illustrates NIR images of RH30
rhabdomyosarcoma xenograft from mouse that was not injected with CTX:Cy5.5 (top) and a mouse that received 0.2 ml of 10 μM CTX:Cy5.5 1.5 days prior to imaging; FIGURE 5E illustrates confocal images of the corresponding tumors from mice that were uninjected (left) and injected (right); and FIGURE 5F is a histopathologic analysis of rhabdomyosarcoma xenograft;
FIGURE 6 are images of 9L glioma flank tumors imaged with a representative chlorotoxin fluorophore conjugate of the invention (CTX:Cy5.5) 24 hours after injection, showing four representative mice with increased signal in tumor (RET) compared to adjacent non-neoplastic tissue (REBG), at this time point, signal from tumor was 2.1 +/- 0.2 (mean +/- SEM, n = 16), the bright regions outside the red circle are from kidney, through which conjugate is excreted;
FIGURES 7A- 7E illustrates a comparison of three fluorophores conjugated to chlorotoxin; FIGURE 7A shows no tumor-specific signal is seen with CTX:fluorescein in mice bearing 9L gliomas within the first hour after imaging; FIGURE 7B illustrates a mouse on the left was injected with CTX:fluorescein directly into the tumor to demonstrate that the conjugate was emitting and being detected properly; FIGURE 7C illustrates a mouse with 9L glioma imaged within 1 hour after injection of CTX: ALEXA- 680 showing signal in tumor; FIGURE 7D is an image 24 hours after injection, excellent signal is observed from CTX:Cy5.5 in tumor compared to opposite non-neoplastic flank (the signal above the tumor is from kidney excretion of bioconjugate), a weaker signal from tumor is seen in ALEXA-680 treated mouse #2, but not #1, reinjection of mouse #1 resulted in rapid clearance of conjugate from non-neoplastic and tumor tissue showing that the conjugate is rapidly cleared in this mouse; and FIGURE 7E are images of the same animals as panel FIGURE 7D, signal remains in CTX:Cy5.5-injected mouse, but no tumor-specific signal is observed in CTX:ALEXA-680-injected mice; taken together, the data indicate that no tumor specific signal is seen with CTX:Fluorescein and that a weak signal from CTX:ALEXA-680 is fleeting compared to CTX:Cy5.5 indicating that the CTX:Cy5.5 conjugate is superior to other tested conjugates in terms of specific distribution to tumor and overall duration of tumor signal; FIGURES 8A and 8B provide genetic evidence that MMP-2 is involved in CTX binding to cancer cells; FIGURE 8A shows MCF-7 breast cancer cell stained with an antibody against MMP-2 (green) and CTX:Cy5.5 (red) shows minimal MMP-2 and minimal CTX:Cy5.5 binding, the nucleus is stained with DAPI to assist with cell
localization in the image; and FIGURE 8B shows MCF-7 breast cancer cell following transfection with a plasmid that encodes MMP-2, staining with the antibody against MMP-2 shows that the transfection resulted in MMP-2 expression in this cell (green), CTX:Cy5.5 staining (red) is much higher than in any of the control cells, yellow shows cell regions in which MMP-2 signal and CTX:Cy5.5 signal are overlapping, no DAPI stain is shown to optimize visualization of MMP-2 and CTX:Cy5.5 binding;
FIGURES 9A and 9B illustrate HPTLC of phospholipid standards and lipids isolated from various cell lines as indicated; FIGURE 9A is an image of a HPTLC plate was developed in chloroform:methanol: water (65:25:4) and lipids were visualized with the lipophilic dye, primulin; and FIGURE 9B is an image pf a HPTLC overlay of lipids with IuM CTX:Cy5.5; abbreviations: PS, phosphatidylserine; PI, phosphatidylinositol: PG, phosphatidylglycerol; PE, phosphatidylethanolamine; PIP2, phosphatidylinositol 4,5-bisphosphate; PC, phosphatidylcholine; SM, sphingomyelin;
FIGURES 10A-10E illustrate specific CTX:Cy5.5 binding in brain tumors compared to normal brain on histologic sections; FIGURE 1OA, hematoxylin and eosin (H&E) stained section of glioma; FIGURE 1OB, CTX:Cy5.5 staining of same glioma; FIGURE 1OC, Cy5.5 alone does not stain glioma; FIGURE 10D, H&E stained section of normal brain from same patient; and FIGURE 1OE, CTX:Cy5.5 does not stain normal brain; FIGURE 11 illustrates MMP-2 and MMP-9 activity in mouse tumors and normal tissue; gelatinase assays were conducted to evaluate MMP-2 expression in the tissues listed above; MMP-2 activity was detected in all cancer foci that were detected by CTX:Cy5.5, but not corresponding non-neoplastic tissue; and MMP-9 activity was detected in mouse medulloblastoma tumors (SmoAl) and prostate tumor, but not xenograft tumors or normal tissues;
FIGURE 12 illustrates MMP-2 and MMP-9 activity in cell lines and media from cell lines. Top: gelatinase activity in cells separated from media shows very little MMP-2 activity in 9L cells and much more activity in U87 cells despite the fact that 9L cells bind CTX:Cy5.5 as well as U87cells. Bottom: Much higher levels of MMP-2 and MMP-9 in media of both 9L and U87 cells than in cell pellets, Together this suggested that secreted MMPs may play an important role in CTX:Cy5.5 binding to cancer cells; and
FIGURES 13A-13F illustrate CTX:Cy5.5 in media from cells with high levels of secreted MMP-2 and MMP-9 stains cells that are negative for CTX:Cy5.5 staining alone; FIGURE 13A shows MCF-7 cells incubated with CTX:Cy5.5 fail to emit in the near infrared (Cy5.5) spectrum (red), nuclei are stained blue with DAPI; FIGURE 13B shows a sister plate of MCF-7 cells incubated with the same amount of CTX:Cy5.5 as in FIGURE 13A, except this CTX:Cy5.5 was transferred in media after 24 hour exposure to 9L glioma cells (CTX:Cy5.5 stains MCF-7 cells under this condition); FIGURE 13C shows a sister plate of MCF-7 cells stained with CTX:Cy5.5 using conditioned media from U87 cells; FIGURE 13D shows CTX:Cy5.5 staining of HeLa cells, no red staining indicates absence of CTX:Cy5.5 signal; FIGURE 13E shows a sister plate of HeLa cells stained with CTX:Cy5.5 in conditioned media from 9L cells; and FIGURE 13F shows a sister plate of HeLa cells stained with CTX:Cy5.5 in conditioned media from U87 cells.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues, compositions that include the chlorotoxin conjugate, and methods for using the chlorotoxin conjugate.
In one aspect, the present invention provides a chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues. The chlorotoxin is a targeting agent that directs the conjugate to a tissue of interest. In one embodiment, the chlorotoxin conjugate of the invention includes one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin.
The chlorotoxin may be native chlorotoxin, synthetic chlorotoxin, or recombinant chlorotoxin. Chlorotoxin fragments and variants having chlorotoxin binding activity (e.g., specificity and affinity to cancerous tissues) may also be used.
As used herein, the term "red or near infrared emitting fluorescent moiety" refers to a fluorescent moiety having a fluorescence emission maximum greater than about 600 nm. Fluorescent chlorotoxin conjugates having shorter wavelength (e.g., from about 500 to about 600 nm) emitting fluorescent moieties are useful in histochemical imaging. These conjugates may be useful less for in vivo imaging in humans and animals where longer wavelength (e.g., greater than about 600 nm) emitting fluorescent moieties are preferred.
In certain embodiments of the chlorotoxin conjugate, the fluorescent moieties are derived from fluorescent compounds characterized by emission wavelength maxima greater than about 600 run to avoid autofluorescence, emission that travels through millimeters to one centimeter of tissue/blood/fluids, emission that is not absorbed by hemoglobin, other blood components, or proteins in human or animal tissue.
The fluorescent moiety is covalently coupled to the chlorotoxin to allow for the visualization of the conjugate by fluorescence imaging. The fluorescent moiety is derived from a fluorescent compound. Suitable fluorescent compounds are those that can be covalently coupled to a chlorotoxin without substantially adversely affecting the targeting and binding function of the chlorotoxin conjugate. Similarly, suitable fluorescent compounds retain their fluorescent properties after conjugation to the chlorotoxin.
In one embodiment, the fluorescent moiety is a cyanine moiety. Cyanine compounds are characterized by their relative high extinction coefficients and favorable fluorescence quantum yields. The fluorescence emission wavelength maximum for a cyanine compound varies as a function of the cyanine structure. Depending on the particular cyanine compound, the fluorescence emission wavelength maxima can vary from the green (about 490 nm) to the near infrared (about 740 nm). hi the practice of the methods of the invention, cyanine compounds having fluorescence emission maxima in the far red (about 650 nm) to the near infrared (about 750 nm) are preferred. At these emission wavelengths, background fluorescence from the local environment is minimal and tissues of interest are relatively transparent. Because of the relative transparency of the tissues of interest at these wavelengths, excitation and fluorescence emission visualization is maximized and relatively greater amounts of tissue targeted by the conjugate of the invention can be observed compared to other conjugates utilizing fluorescent compounds having emission at shorter wavelengths (less than 600 nm).
Suitable cyanines include the CYDYE fluors commercially available from GE Healthcare under the designation Cy2 (506 nm); Cy2 (506 nm); Cy3 (570 nm); Cy3B (572 nm); Cy3.5 (596 nm); Cy5 (670 nm); Cy5.5 (675 nm); and Cy7 (694 nm) (emission maxima in parentheses). In one embodiment, the cyanine compound is Cy5.5. The preparation of a representative cyanine-chlorotoxin conjugate is described in Example 1.
In one embodiment, the fluorescent moiety is a sulfonated xanthene moiety. Sulfonated xanthene compounds suitable for use in the practice of the invention are
described in U.S. Patent No. 6,130,101, expressly incorporated herein by reference in its entirety, and commercially available under the designation ALEXA FLUOR from Molecular Probes, Inc., Eugene, OR. ALEXA FLUOR is the designation for a family of fluorophores that are characterized by their relative high extinction coefficients and favorable fluorescence quantum yields. The fluorescence emission wavelength maximum for a sulfonated xanthene compound varies as a function of the compound's structure. Depending on the particular sulfonated xanthene compound, the fluorescence emission wavelength maxima can vary from the green (about 450 nm) to the near infrared (about 780 nm). In the practice of the methods of the invention, ALEXA FLUOR compounds having fluorescence emission maxima in the far red (about 650 nm) to the near infrared (about 750 nm) are preferred.
Suitable sulfonated xanthene compounds include ALEXA FLUORS, such as ALEXA FLUOR 350 (442 nm), ALEXA FLUOR 405 (421 nm), ALEXA FLUOR 488 (539 nm), ALEXA FLUOR 500 (525 nm), ALEXA FLUOR 514 (540 nm), ALEXA FLUOR 532 (554 nm), ALEXA FLUOR 546 (575 nm), ALEXA FLUOR 555 (565 nm), ALEXA FLUOR 568 (603 nm), ALEXA FLUOR 594 (617 nm), ALEXA FLUOR 610 (628 nm), ALEXA FLUOR 633 (647 nm), ALEXA FLUOR 635 (645 nm), ALEXA FLUOR 647 (668 nm), ALEXA FLUOR 660 (690 nm), ALEXA FLUOR 680 (702 nm), ALEXA FLUOR 700 (719 nm), and ALEXA FLUOR 750 (779 nm) (emission maxima in parentheses). In one embodiment, the sulfonated xanthene is ALEXA FLUOR 680. Representative sulfonated xanthene-chlorotoxin conjugates can be prepared in manner analogous to that described for cyanine conjugation in Example 1 and as further described in The Handbook - A Guide to Fluorescent Probes and Labeling Technologies, Richard P. Haugland (Molecular Probes, Inc., a subsidiary of Invitrogen Corp.). Suitable fluorescent compounds include a functional group that renders the compound chemically reactive toward the chlorotoxin. Suitable functional groups include the N-hydroxysuccinimide (NHS) group for covalent coupling to amine groups, the maleimide group for covalent coupling to thiol groups, and the hydrazide group for covalent coupling to aldehyde groups. Preferably, the fluorescent compound useful in preparing the conjugate of the invention includes a single reactive functional group (e.g., mono-NHS ester). It will be appreciated that other conjugating chemistries are suitable for making the chlorotoxin conjugate of the present invention.
Suitable conjugates of the invention include from about 1 to about 3 fluorescent moieties/chlorotoxin. In one embodiment, the conjugate include about 1 fluorescent moiety.
The preparation of a representative chlorotoxin conjugate of the invention is described in Example 1. hi vitro imaging using a representative chlorotoxin conjugate of the invention is described in Example 2. hi vivo imaging using a representative chlorotoxin conjugate of the invention is described in Example 3. The involvement of
MMP-2 in chlorotoxin binding is described in Example 4. hi another aspect, the invention provides a fluorescent chlorotoxin conjugate having a prolonged half-life in vivo. The fluorescent chlorotoxin conjugate includes one or more fluorescent moieties covalently coupled to a chlorotoxin. hi one embodiment, the conjugate has a sufficiently long half-life to enable biophotonic imaging of cancer from about 4 to about 14 days after administration of the chlorotoxin conjugate. hi another aspect of the invention, compositions that include the chlorotoxin conjugate are provided. The composition is suitable for administration to a human and animal subjects and includes pharmaceutically acceptable carrier. The composition includes a pharmacologically effective amount of a chlorotoxin conjugate. An effective amount can be routinely determined by established procedures. An effective amount is an amount sufficient to occupy chlorotoxin binding sites in cancer cells, but low enough to minimize non-specific binding to non-neoplastic tissues. An effective amount optimizes signal-to-noise ratio for intra-operative imaging. hi other aspects, the invention provides methods for using the chlorotoxin conjugate to detect and treat tissues of interest.
The invention provides methods for detecting a tissue using the chlorotoxin conjugates. The chlorotoxin conjugates of the invention target and are bound by chlorotoxin binding sites. It will be appreciated that chlorotoxin binding sites may take two forms: sites that bind chlorotoxin and sites that bind the chlorotoxin conjugates of the invention. It will be appreciated that chlorotoxin binding sites may be distinct from chlorotoxin conjugate binding sites. In one embodiment, a method for differentiating foci of cancers that express chlorotoxin binding sites from non-neoplastic tissue is provided. The method includes the steps of:
(a) contacting a tissue of interest with a chlorotoxin conjugate having affinity and specificity for cells that express chlorotoxin binding sites, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin; and (b) measuring the level of binding of the chlorotoxin conjugate, wherein an elevated level of binding, relative to normal tissue, is indicative that the tissue is neoplastic.
In one embodiment, a method for detecting cancers that express chlorotoxin binding sites is provided. The method includes the steps of: (a) contacting a tissue of interest with a chlorotoxin conjugate having affinity and specificity for cells that express chlorotoxin binding sites, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin; and
(b) measuring the level of binding of the chlorotoxin conjugate, wherein an elevated level of binding, relative to normal tissue, is indicative that the tissue is neoplastic.
In one embodiment, a method for detecting cells expressing matrix metalloproteinase (MMP-2) protein complex is provided. The method includes the steps of: (a) contacting a tissue of interest with a chlorotoxin conjugate having affinity and specificity for matrix metalloproteinase (MMP-2) protein complex, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin; and
(b) measuring the level of binding of the chlorotoxin conjugate, wherein an elevated level of binding, relative to normal tissue, is indicative of the presence of a tumor expressing matrix metalloproteinase (MMP-2) protein complex.
The matrix metalloproteinase (MMP-2) protein complex may be membrane bound.
In one embodiment, a method for determining the location of cancer cells that express chlorotoxin binding sites in a patient intra-operatively is provided. The method includes the steps of:
(a) administering a pharmaceutical composition to a patient, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and an
amount of a chlorotoxin conjugate sufficient to image cancer cells that express chlorotoxin binding sites in vivo, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin; (b) measuring the level of binding of the chlorotoxin conjugate by fluorescence imaging to determine the location of cancer cells that express chlorotoxin binding sites, wherein an elevated level of binding, relative to normal tissue, is indicative of the presence of cancer cells that express chlorotoxin binding sites; and
(c) surgically removing from the patient at least some cells that express chlorotoxin binding sites located by fluorescence imaging.
The imaging methods of the invention for detection of cancer foci is applicable to mouse and other animal models of cancer as well as to veterinary practice.
The invention provides methods for treating a tissue using the chlorotoxin conjugates. In one embodiment, the invention provides a method for treating a cancer that expresses chlorotoxin binding sites in a patient, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
In one embodiment, the invention provides a method for treating a cancer that expresses chlorotoxin binding sites, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
In one embodiment, the invention provides a method for treating a tumor expressing matrix metalloproteinase (MMP-2) protein complex, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
In one embodiment, the invention provides a method for inhibiting invasive activity of cells that express chlorotoxin binding sites, comprising administering to cells that express chlorotoxin binding sites an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate of the invention and a pharmaceutically acceptable carrier.
The methods of treatment of the invention are applicable to human and animal subjects in need of such treatment.
The chlorotoxin conjugates of the invention can be used to detect and treat various cancers (e.g., prostate cancer, sarcomas, hematological malignancies, and leukemias) and various neuroectodermal tumors (e.g., glioma, meningioma, ependymonas, medulloblastoma, neuroblastoma, glioblastoma, ganglioma, pheochromocytoma, melanoma, Ewing's sarcoma, small cell lung carcinoma, and metastatic brain tumors).
Based on current literature, virtually every type of malignant cancer showing
MMP-2 expression is expected to specifically bind the chlorotoxin conjugates of the invention (e.g., CTX:Cy5.5). These malignant cancers include gliomas, astrocytomas medulloblastomas, choroids plexus carcinomas, ependymomas, other brain tumors, neuroblastoma, head and neck cancer, lung cancer, breast cancer, intestinal cancer, pancreatic cancer, liver cancer, kidney cancer, sarcomas (over 30 types), osteosarcoma, rhabdomyosarcoma, Ewing's sarcoma, carcinomas, melanomas, ovarian cancer, cervical cancer, lymphoma, thyroid cancer, anal cancer, colo-rectal cancer, endometrial cancer, germ cell tumors, laryngeal cancer, multiple myeloma, prostate cancer, retinoblastoma, gastric cancer, testicular cancer, and Wilm's tumor.
The fluorescent chlorotoxin conjugate of the invention may include other useful agents. Other useful agents include diagnostic agents and therapeutic agents. Suitable diagnostic agents include agents that provide for the detection of the nanoparticle by methods other than fluorescence imaging. Other suitable diagnostic agents include radiolabels (e.g., radio isotopically labeled compounds) such as 125I, 4C, and 31P, among others.
Suitable therapeutic agents include cytotoxic agents. Representative therapeutic agents include chemotherapeutic agents such as methotrexate, docetaxel, cisplatin, and etoposide, among others. Other therapeutic agents include nucleic acid molecules (e.g., DNAs and RNAs, such as siRNAs) for specific cancers and diseases.
Surgery remains a principal component of cancer therapy. Recent advances in surgical oncology have included image guidance and minimally invasive approaches such as endoscopy which limit morbidity and improve the extent of resection. These procedures greatly depend on the judgment of the surgeon for visual delineation of the tumor/normal tissue interface. Improvements in the identification and excision of cancerous tissue translate into improved surgical outcomes. The "tumor painting"
technique of the present invention combines an intuitive visual guide for the surgeon with the potential for significant improvement in accuracy and safety by virtue of its molecular precision.
The present invention provides a chlorotoxin conjugate (e.g., CTX:Cy5.5) that enables real time biophotonic imaging of malignant cancer foci as small as 1.5 mm. The same agent clearly delineated malignant prostate cancer cells from normal prostate at single cell resolution in human surgical biopsy samples, establishing the relevance of the mouse studies to human disease. See Examples 2 and 3. All tissues sent to pathology tagged as cancer based on CTX:Cy5.5 signal were cancerous and all adjacent normal tissues were histologically normal. The resolution of cancer foci from normal tissue under simulated operating conditions was exquisite.
Real-time intraoperative cancer detection would not be feasible if circulating unbound conjugate spilled into the operating field each time a blood vessel is severed. An unexpected and welcome finding was the long duration of conjugate activity. Peptides are often considered poor candidates for diagnostics or therapeutics because many have a short half-life. The observation that glioma cells were illuminated 32 days after conjugate injection raised the possibility that CTX:Cy5.5, a representative chlorotoxin conjugate of the invention, could be used as a "tumor paint" to enable surgeons to detect residual disease or small foci of disease intraoperatively. Chlorotoxin (CTX) was previously shown to bind to neuroectodermal tumor cells, but has not been shown to bind to prostate cancer, colon cancer or sarcomas. The binding of CTX to human medulloblastoma cells contradicts previous reports that MMP-2 is not highly expressed in medulloblastoma. As described herein, medullablastoma cells do express MMP-2. Furthermore, confocal microscopy of multiple types of cancer showed binding to nearly every cancer cell, which was higher than expected based on previous reports of heterogeneous MMP-2 expression. It remains unclear whether CTX binds to other MMPs or bind to glioma-specific chloride channels. Whatever the scope of targets, the methods of the invention show that following excretion of unbound CTX:Cy5.5, which took approximately 5 days in mice, all normal organs except kidney emit minimal signal.
Chlorotoxin was originally thought to bind to a chloride channel and early studies indicated that it impaired transmembrane chloride flux. The use of a chloride channel toxin that crosses the blood brain barrier would obviously be problematic for clinical
application of CTX-based probes. Recent work has determined that chlorotoxin does not bind to chloride ion channels and that the original report was scientifically flawed. In the practice of the methods of the invention, specific binding of CTX:Cy5.5 to non-neoplastic brain tissue was minimal. Furthermore, no neurologic or behavioral deficits and no neuropathology in brains of mice that had been exposed to CTX:Cy5.5 were observed. This is consistent with the absence of neurotoxicity in other studies, including one that involved direct injection of CTX into mouse brain. No pathologic changes in other organs and no alteration of electrolytes, blood counts, or kidney and liver function tests were observed. The chlorotoxin conjugate of the invention enables detection and monitoring of a variety of cancers in mouse models. This approach adds particular value to genetically engineered mouse (GEM) models of human cancers, which in contrast to xenograft or mutagenic models of cancer, develop in situ cancers as a result of genetic manipulation that recapitulates human disease. A particular advantage of GEM mice is that tumors can be studied from early to advanced stages to better understand the evolution of growth, angiogenesis, local invasion, metastases, drug response and drug resistance.
Unfortunately, the paucity of non-invasive imaging approaches has sharply limited full utilization of GEM cancer models. For example, prior to the development of the chlorotoxin conjugates of the invention, the primary means of monitoring SmoAl mice for medulloblastoma was the neurologic exam. In these mice, the first neurologic signs typically occur only when the tumor mass is so large that death occurs shortly thereafter. In addition, micro-CT fails to distinguish tumors in the posterior fossa of mice and MRI is costly. The ability to detect early stage tumors for molecular or therapeutic studies can be dramatically improved by a real-time imaging technique such as provided by the methods of the invention.
The present invention provides a chlorotoxin conjugate (e.g., CTX:Cy5.5, a representative chlorotoxin conjugate of the invention) that enabled real-time biophotonic imaging of xenografted gliomas and sarcomas. The chlorotoxin conjugate also effectively distinguished autochthanous medulloblastoma, prostate, and intestinal cancers from normal tissues in genetically engineered mice (GEM). Micrometastases to lung and lymph nodes were readily detected. Human tumor specimens showed perfect correlation between CTX:Cy5.5 binding and rests of prostate cancer cells. These data, coupled with favorable distribution and toxicity studies demonstrate the effectiveness of chlorotoxin
conjugates of the invention in intra-operative detection and optimal resection of cancerous tissues.
The following examples are provided for the purpose of illustrating, not limiting, the present invention. EXAMPLES
Example 1 The Preparation and Characterization of a Representative Chlorotoxin Conjufiate:
CTX:Cv5.5
A representative chlorotoxin conjugate of the invention, CTX:Cy5.5 was prepared by conjugating Cy5.5 to chlorotoxin.
The conjugate was synthesized using a mixture of CTX (Alomone Labs, Israel, 250 ul of 2 mg/ml in 50 mM bicarbonate buffer, pH 8.5) and Cy5.5-NHS ester (Amersham Biosciences, Sweden, 43 ul of 10 mg/ml in anhydrous dimethylformamide). Conjugation was performed in dark at room temperature for 1 hour. Unconjugated dye was removed by dialysis against PBS (3 times) using Slide- A-Lyzer (Pierce Biotechnology, IL) membrane (Mr3 cutoff, 3500) for 9 hours at 4 0C. Samples were diluted with PBS to produce 1 and 10 uM of CTX solution and filtered with a 0.2 um syringe filter before use.
The concentration of CTX was quantified using bicinchoninic acid (BCA) assay (Pierce Biotechnology, Rockford, IL). The concentration of fluorophore in the same solution was quantified and evaluated to determine the ratio of fluorophore/CTX.
Example 2
In Vitro Imaging with a Representative Chlorotoxin Conjugate: CTX:Cy5.5
9L/lacZ gliosarcoma cells (ATCC, VA) and primary human foreskin fibroblast (HFF) were maintained in DMEM and RPMI medium both supplemented with
1% sodium pyruvate, 1% streptomycin/penicillin and 10% FBS (Hyclone, UT), respectively. 2 x 105 cells were seeded on sterile cover slips 36 hrs prior to labeling and confocal microscopy. Cells were cultured with 1 ml of CTX:CY5.5 conjugate (IuM) for
2 hours in a 37C humidified incubator maintained at 5% CO2. Cover slips were washed 2 times in cell culture medium and 2 times in PBS buffer. Following this step, cell membranes were stained with l μM solution of FM 1-43FX (Molecular Probes, OR) for
20 min in dark at room temperature, washed 2 times in PBS and fixed in
4% paraformaldehyde. Cellular nuclei were stained with 4',6-diamidino-2-phenyindole (DAPI, Sigma Aldrich, MO).
Confocal images were acquired using a DeltaVision SA3.1 Wide-Field
Deconvolution Microscope (Applied Precision, WA) equipped with DAPI, TRITC, and Cy5 filters. Image processing was performed using SoftWoRX (Applied Precision, WA).
Biophotonic imaging of glioma. To determine whether CTX retained specific binding to glioma cells after conjugation to Cy5.5, we incubated the conjugate with
9L glioma cells and primary fibroblasts and evaluated binding by NIR microscopy. AU
9L glioma cells exposed to CTX:Cy5.5 emitted signal in the NIR spectrum (FIGURE 2A) whereas no signal was detected from fibroblasts treated with the same concentration of conjugate (FIGURE 2B). Binding of CTX:Cy5.5 to 9L glioma cells was blocked by pre-incubation with 1,10-phenanthroline, a specific pharmacologic inhibitor of MMP-2 (not shown). Together these data indicate that CTX retains MMP-specific binding capacity following conjugation to Cy5.5. Example 3
In Vivo Imaging with a Representative Chlorotoxin Conjugate: CTX:Cy5.5 Animal models. All mouse studies were conducted in accordance with IACUC approved protocols. Subcutaneous xenografts were established in nu/nu (nude) mice using 9L, a rat gliosarcoma cell line (ATCC), and RH30, a rhabdomyosarcoma cell line. The xenografts were established using 1 million 9L or RH30 cells suspended in serum free media and matrigel at a 1:1 ratio. Intracranial xenografts were established by stereotaxic injection of 1 million 9L cells suspended in 10 μl PBS into the brain 3 mm lateral and posterior to the bregma. ND2:SmoAl medulloblastoma mice, TRAMP prostate cancer mice and Apcy<J5lW intestinal adenoma and adenocarcinoma mice were as previously described. See, Fodde, R., et al., A targeted chain-termination mutation in the mouse Ape gene results in multiple intestinal tumors. Proc. Natl. Acad. ScL U.S.A., 1994. 91(19): p. 8969-73; Greenberg, N.M., et al., Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. U.S.A., 1995. 92(8): p. 3439-43; Kaplan-Lefko, PJ., et al., Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate, 2003. 55(3): p. 219-37.; Hallahan, A.R., et al., The SmoAl mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res., 2004. 64(21): p. 7794-800; each expressly incorporated herein by reference in its entirety.
In vivo imaging methods. CTX:Cy5.5 (0.1 - 0.2 ml of 10-20 μM) was administered intravenously by tail vein injection. Biophotonic images were obtained on the Xenogen IVIS system (Alameda, CA). Mice were anesthetized with 1 to 2.5% isoflurane (Abbott Labs, IL) before they were placed in the imaging chamber and imaged at various time points postinjection. Relevant organs and tumors were dissected from some of the animals and fluorescence image were obtained immediately following dissection. In time course experiments, all images were captured using identical system settings and fluorescence emission was normalized to photons per second per centimeter squared per steradian (p/s/cm2/sr). All experiments were repeated multiple times and representative images are shown in the figures.
The in vivo activity of CTX:Cy5.5 in mice with 9L glioma xenografts. Following tail vein injection of 0.1 ml of 10 μM conjugate, the conjugate distributed rapidly throughout the body. At all time points, NIR emission was higher in xenografts than in surrounding tissue. Specific binding to glioma cells was observed up to 32 days after tail vein injection, which was substantially longer than that seen in the remainder of the body (4-5 days) (FIGURE 2C). Brain xenografts showed clear distinction between tumor and normal brain under conditions that can be reproduced in human surgical operating suites (FIGURE 2D). Histologic analysis confirmed glioma invasion in brain of xenograft mice, but not controls (FIGURE 2E). Specific binding of CTX:Cy5.5 was six-fold lower when mice were pre-treated with the MMP-2 blocker, 1,10-phenanthroline indicating that imaging reflected binding of CTX:Cy5.5 to tumor cells rather than simply measuring increased blood flow in neo vascularized tumors (FIGURE 2F).
Non-invasive imaging of medulloblastoma through cranial bone. CTX:Cy5.5 was tested in a genetically precise autochthonous mouse model of medulloblastoma. In these mice, medulloblastomas arise in the cerebellum due to transgenic expression of constitutively active smoothened, a mediator of sonic hedgehog activity. In these mice, tumors were detected through intact skull and scalp and the level of NIR emission correlated with the size of each tumor (FIGURES 3A-D and not shown). Because these tumors arise in the absence of surgical disruption of the blood brain barrier, it was concluded that CTX:Cy5.5 enters mouse medulloblastoma tissue at concentrations suitable for real time imaging and that intracranial tumors can be readily detected noninvasively.
Prostate tissue imaging. Normal and cancerous human prostate tissue samples were collected and handled in accordance with Human Subjects HRB approved protocols. Sections were incubated with 1 μM CTX:Cy5.5 conjugate in 5% normal goat serum buffer for 45 minutes. Unbound conjugate was reduced by washing slides 3 times for 5minutes in PBS buffer. Signal was detected by fluorescence microscopy and correlated to adjacent sections stained with hematoxylin and eosin (H&E).
For mouse experiments, tissues were fixed in freshly prepared 4% paraformaldehyde and stained with H&E per standard clinical laboratory protocol. Confocal microscopy was performed on a Zeiss LSM 510 (Carl Zeiss, NY) microscope using a 633 ran HeNe laser lines for excitation and a 650-710 nm band pass filter for emission collection through a photomultiplier tube capturing system. NIR signal was translated into red pseudocolor to enable detection in the visible spectrum.
Imaging of autochthanous prostate cancer and metastases. MMP-2 is expressed by cancers that develop from diverse organ sites, though chlorotoxin binding has only been assessed in neuroectodermal tumors. To determine whether CTX labels prostate cancer cells, CTX:Cy5.5 binding to sections of surgically-derived human prostate cancer was compared to non-neoplastic prostate epithelium. No specific binding was observed in normal prostate tissue, whereas high levels of CTX:Cy5.5 were observed in islands of cancer cells (FIGURE 4A). Adjacent sections revealed perfect correlation between rests of cancer cells detected by CTX:Cy5.5 and standard histologic staining (FIGURE 4A).
GEM model of prostate cancer. The results for CTX:Cy5.5 binding to human prostate cancer sections lead to evaluation of the conjugate in a GEM model of prostate cancer. In transgenic mice that express the SV40T gene in prostate epithelium, CTX:Cy5.5 illuminated the primary prostate cancer as well as lung and lymphatic metastases (FIGURES 4B-D). CTX:Cy5.5 binding correlated with the histological presence of neoplastic cells in the primary and distant organs (FIGURE 4C). Microscopic foci of cancer cells in lymphatic channels and lymph nodes were easily detected (FIGURES 4D-E).
CTX:Cy5.5 binding in adenocarcinoma and sarcoma. To further assess the spectrum of cancer that can be imaged by CTX:Cy5.5, NIR emission in a GEM familial adenomatous polyposis (FAP) model, the Apc1638N mouse, and in a xenograft sarcoma model was evaluated. In Apc1638N mice, intestinal neoplasms could not be resolved by noninvasive imaging because of autofluorescence of the intestinal contents. Ex vivo
analysis of intestine that was free of intestinal contents showed exquisite delineation of 3-5 mm diameter cancer nodules and no appreciable signal from otherwise normal intestine (FIGURES 5A-C). Microscopic analyses of the rhabdomyosarcoma xenograft showed that virtually every cancer cell was brightly illuminated by CTX:Cy5.5 (FIGURES 5D-F).
Biodistribution and Toxicity. CTX and Cy5.5 have previously been administered to human patients in clinical trials, but the pharmacokinetic properties of the conjugate have not previously been studied. Unbound conjugates were fairly evenly distributed through the mouse body during the first 24-96 hours, with the exception that NIR emission from kidney was much higher than any other organ. Confocal microscopy showed that CTX:Cy5.5 was concentrated in the renal collecting system as expected for a compound that is primarily excreted in urine. No other organ showed specific binding of CTX:Cy5.5.
CTX was previously reported to reduce locomotor activity in mice. In this study, mice that were injected with CTX were indistinguishable from control mice in open field observation. To further assess potential CTX toxicity at doses used for optical imaging, complete necropsy was performed on mice two weeks after exposure to CTX. Brain, heart, lungs, kidneys, liver, spleen, and skin were indistinguishable from control mice
(not shown). Laboratory evaluation showed no alteration in hematocrit, platelet count, white blood cell count, electrolytes, liver function or kidney function (not shown). At doses used for optical imaging, no toxicity could be detected in mice.
Example 4
MMP-2 Involvement in Chlorotoxin Conjugate Binding
The involvement of MMP-2 in chlorotoxin conjugate binding is described in this example.
It was previously reported that medulloblastoma cells did not express MMP-2. As described herein, binding of a representative chlorotoxin conjugate of the invention
(CTX:Cy5.5) was observed in mouse medulloblastoma tumors and human medulloblastoma histologic sections. This raised the possibility that MMP-2 was not the target of CTX:Cy5.5, despite a previously published report that CTX binds to MMP-2.
MMP-2 activity was analyzed by gelatinase assays. Gelatinase assays also detect MMP-9 activity. These analyses showed that all tumors that bound CTX:Cy5.5 express MMP-2 and MMP-9 and that autochthanous tumors in genetically engineered
medulloblastoma and prostate cancer models also express MMP-2, but not MMP-9 (see FIGURE 11). Non-neoplastic tissue from mice did not show MMP-2 or MMP-9 activity. This experiment showed that MMP-2 was expressed in tissues that bound CTX:Cy5.5, but not in non-neoplastic tissues that showed only background CTX:Cy5.5 binding.
Pharmacologic inhibitors of MMP-2 reduced CTX:Cy5.5 binding in vitro and in vivo experiments suggesting that MMP-2 may be important for CTX:Cy5.5 binding (see FIGURE 2F and not shown). To further, definitively, determine whether MMP-2 was involved in CTX:Cy5.5 binding, a genetic approach was taken. MCF-7 cells, which minimally express MMP-2 and minimally bind CTX:Cy5.5 (see FIGURES 11 and 8) were transfected with a plasmid that encodes MMP-2. Following transfection, cells expressed high levels of MMP-2 as shown in green in FIGURE 8. Furthermore, MCF-7 cells transfected with MMP-2 plasmid, but not those transfected with control plasmid bound high levels of CTX:Cy5.5 and this signal highly localized with MMP-2 staining. This clearly demonstrates that MMP-2 is important for CTX:Cy5.5 binding.
Observations raised the possibility that MMP-2 may not be the ultimate cellular target of CTX:Cy5.5. First, experiments in 9L glioma cells showed relatively poor co-localization of CTX:Cy5.5 binding and immunofluorescent staining of MMP-2. It is possible that this result is due to steric hindrance between CTX:Cy5.5 and the antibody against MMP-2 or that intracellular MMP-2 was not the ultimate CTX:Cy5.5 target. Furthermore, there was discordance between the amount of CTX:Cy5.5 binding in cells and the amount of MMP-2 expressed in the cells. For example, 9L glioma and U87 glioma both showed high levels of CTX:Cy5.5 binding, yet 9L had low MMP-2 activity and U87 had much higher levels of MMP-2 activity in gelatinase assays (see FIGURE 12). MCF7 cells had very low CTX:Cy5.5 binding, yet the cellular fraction expressed low amounts of MMP-2, not too unlike 9L cells (see FIGURE 12). We further evaluated MMP-2 and MMP-9 levels in media from cells. The amount of CTX:Cy5.5 binding to cells in culture corresponded much better to media levels of MMP-2 activity, which was high in 9L and U87 cells, but low in MCF7 cells (see FIGURE 12). It was hypothesized that the secreted form of MMP-2 was more important for
CTX:Cy5.5 binding to cells than the intracellular form. To test this, CTX:Cy5.5 binding in MCF7 and HeLa cells was compared under the following three conditions. In Condition (1) CTX:Cy5.5 was added directly to MCF7 or HeLa media and incubated for
24 hours under conditions that resulted in high CTX:Cy5.5 binding to 9L or U87 cells. There was minimal staining of MCF7 or HeLa cells under these conditions, hi Condition (2) the same amount of CTX:Cy5.5 was added to media of 9L or U87 cells, incubated for 24 hours, then transferred to MCF7 or HeLa cells. When conditioned media from either 9L or U87 cells was used for staining, both MCF7 and HeLa cells were brightly stained by CTX:Cy5.5 (see FIGURE 13). Because the amount of MMP2 does not change in MCF7 or HeLa cells due to the presence of conditioned media, CTX:Cy5.5 ultimately binds to a target other than MMP-2. There are two major possibilities that are currently being studied: (1) MMP-2 enzymatically alters CTX:Cy5.5 so that it gains affinity for another cellular target; or (2) MMP-2 enzymatically alters molecule(s) in MCF7 or HeLa cells so that they gain affinity for CTX:Cy5.5.
Either way, MMP-2 was shown as important for CTX:Cy5.5 binding, but that it may not be the ultimate cellular target of CTX:Cy5.5.
CTX:Cy5.5 wa observed to bind to a rapidly migrating band on Western analyses that was consistent with a phospholipid band. This raised the possibility that CTX:Cy5.5 bound to a phospholipid. We resolved phospholipids from 4 cell lines as well as appropriate purified phospholipid standards by thin layer chromatography (TLC). The TLC plates were then stained with CTX:Cy5.5. This definitively showed that sphingomyelin and phosphatidyl choline, but not phospho-inositol bisphosphate or other phospholipids were capable of binding CTX:Cy5.5 (see FIGURE 9).
Sphingomyelin and phosphatidylcholine are present in all cells and only a subset of MCF7 and HeLa cells treated with CTX:Cy5.5 conditioned media from 9L and U87 cells showed high levels of signal.
While illustrative embodiments have been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention.
Claims
1. A chlorotoxin conjugate, comprising one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin.
2. The conjugate of Claim 1, wherein the chlorotoxin is selected from the group consisting of native chlorotoxin, synthetic chlorotoxin, recombinant chlorotoxin, and fragments and variants thereof having chlorotoxin binding activity.
3. The conjugate of Claim 1, wherein the fluorescent moiety is a cyanine moiety.
4. The conjugate of Claim 1, wherein the fluorescent moiety is a Cy5.5 moiety.
5. The conjugate of Claim 1, wherein the fluorescent moiety is a sulfonated xanthene moiety.
6. The conjugate of Claim 1, wherein the fluorescent moiety is an ALEXA FLUOR-680 moiety.
7. The conjugate of Claim 1, wherein the conjugate comprises from about 1 to about 3 fluorescent moieties.
8. The conjugate of Claim 1, wherein the conjugate comprises about 1 cyanine moiety.
9. The conjugate of Claim 1, wherein the conjugate comprises about 1 sulfonated xanthene moiety.
10. A fluorescent chlorotoxin conjugate, comprising one or more fluorescent moieties covalently coupled to a chlorotoxin, wherein the conjugate has a half-life in vivo to enable biophotonic imaging of cancer at least about 4 days after administration of the conjugate.
11. A composition, comprising a chlorotoxin conjugate suitable for administration to a human, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin.
12. A method for differentiating foci of cancers that express chlorotoxin binding sites from non-neoplastic tissue, comprising:
(a) contacting a tissue of interest with a chlorotoxin conjugate having affinity and specificity for cells that express chlorotoxin binding sites, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin; and
(b) measuring the level of binding of the chlorotoxin conjugate, wherein an elevated level of binding, relative to normal tissue, is indicative that the tissue is neoplastic.
13. A method for detecting cancers that express chlorotoxin binding sites, comprising:
(a) contacting a tissue of interest with a chlorotoxin conjugate having affinity and specificity for cells that express chlorotoxin binding sites, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin; and
(b) measuring the level of binding of the chlorotoxin conjugate, wherein an elevated level of binding, relative to normal tissue, is indicative that the tissue is neoplastic.
14. A method for detecting cells expressing matrix metalloproteinase (MMP-2) protein complex, comprising:
(a) contacting a tissue of interest with a chlorotoxin conjugate having affinity and specificity for matrix metalloproteinase (MMP-2) protein complex, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin; and
(b) measuring the level of binding of the chlorotoxin conjugate, wherein an elevated level of binding, relative to normal tissue, is indicative of the presence of a tumor expressing matrix metalloproteinase (MMP-2) protein complex.
15. A method for determining the location of cancer cells that express chlorotoxin binding sites in a patient intra-operatively, comprising:
(a) administering a pharmaceutical composition to a patient, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and an amount of a chlorotoxin conjugate sufficient to image cancer cells that express chlorotoxin binding sites in vivo, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin;
(b) measuring the level of binding of the chlorotoxin conjugate by fluorescence imaging to determine the location of cancer cells that express chlorotoxin binding sites, wherein an elevated level of binding, relative to normal tissue, is indicative of the presence of cancer cells that express chlorotoxin binding sites; and
(c) surgically removing from the patient at least some cells that express chlorotoxin binding sites located by fluorescence imaging.
16. A method for treating a cancer that expresses chlorotoxin binding sites comprising, administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate and a pharmaceutically acceptable carrier, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin.
17. A method for treating a tumor expressing matrix metalloproteinase (MMP- 2) protein complex, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate and a pharmaceutically acceptable carrier, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin.
18. A method for inhibiting invasive activity of cells that express chlorotoxin binding sites, comprising administering to cells that express chlorotoxin binding sites an effective amount of a pharmaceutical composition comprising the chlorotoxin conjugate and a pharmaceutically acceptable carrier, wherein the chlorotoxin conjugate comprises one or more red or near infrared emitting fluorescent moieties covalently coupled to a chlorotoxin.
19. The methods of Claims 12, 13, 15, 16, and 18, wherein the cancer that expresses chlorotoxin binding sites is selected from gliomas, astrocytomas medulloblastomas, choroids plexus carcinomas, ependymomas, brain tumors, neuroblastomas, head and neck cancers, lung cancers, breast cancers, intestinal cancers, pancreatic cancers, liver cancers, kidney cancers, sarcomas, osteosarcomas, rhabdomyosarcomas, Ewing's sarcoma, carcinomas, melanomas, ovarian cancers, cervical cancers, lymphomas, thyroid cancers, anal cancers, colo-rectal cancers, endometrial cancers, germ cell tumors, laryngeal cancers, multiple myelomas, prostate cancers, retinoblastomas, gastric cancers, testicular cancers, and Wilm's tumor.
20. The methods of Claims 12, 13, 15, 16, and 18, wherein the cancer that expresses chlorotoxin binding sites is selected from gliomas, medulloblastomas, sarcomas, prostate cancer, and intestinal cancer.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT06739100T ATE502048T1 (en) | 2005-04-22 | 2006-03-20 | FLUORESCENT CHLOROTOXIN CONJUGATE AND METHOD FOR INTRAOPERATIVE VISIBILITY OF CANCER |
EP06739100A EP1877428B1 (en) | 2005-04-22 | 2006-03-20 | Cyanine- chlorotoxin conjugate and method for intra-operative visualization of cancer |
DE602006020710T DE602006020710D1 (en) | 2005-04-22 | 2006-03-20 | FLUORESCENT CHLOROTOXIN CONJUGATE AND METHOD FOR THE INTRAOPERATIVE VIEW OF CANCER |
US11/897,721 US8778310B2 (en) | 2005-04-22 | 2007-08-31 | Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer |
US14/273,374 US20140241993A1 (en) | 2005-04-22 | 2014-05-08 | Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67428005P | 2005-04-22 | 2005-04-22 | |
US60/674,280 | 2005-04-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/897,721 Continuation US8778310B2 (en) | 2005-04-22 | 2007-08-31 | Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006115633A2 true WO2006115633A2 (en) | 2006-11-02 |
WO2006115633A3 WO2006115633A3 (en) | 2006-12-28 |
Family
ID=36609637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/010170 WO2006115633A2 (en) | 2005-04-22 | 2006-03-20 | Cyanine-chlorotoxin conjugate and method for intra-operative fluorescent visualization of cancer |
Country Status (6)
Country | Link |
---|---|
US (3) | US20070154965A1 (en) |
EP (1) | EP1877428B1 (en) |
AT (1) | ATE502048T1 (en) |
DE (1) | DE602006020710D1 (en) |
ES (1) | ES2360519T3 (en) |
WO (1) | WO2006115633A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007106142A3 (en) * | 2006-02-24 | 2007-12-21 | Mallinckrodt Inc | Process for using optical agents |
WO2008139207A2 (en) * | 2007-05-16 | 2008-11-20 | Ge Healthcare As | Labelled hgf binding peptides for imaging |
WO2009021136A1 (en) * | 2007-08-07 | 2009-02-12 | Transmolecular, Inc. | Chlorotoxins as drug carriers |
EP2211913A2 (en) * | 2007-10-12 | 2010-08-04 | Transmolecular, Inc. | Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors |
EP2265630A2 (en) * | 2008-04-14 | 2010-12-29 | The General Hospital Corporation | Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma |
WO2011142858A2 (en) | 2010-05-11 | 2011-11-17 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
WO2013003507A1 (en) * | 2011-06-27 | 2013-01-03 | Morphotek, Inc. | Multifunctional agents |
US8778310B2 (en) | 2005-04-22 | 2014-07-15 | University Of Washington | Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer |
WO2015042202A1 (en) | 2013-09-17 | 2015-03-26 | Blaze Bioscience, Inc. | Chlorotoxin conjugates and methods of use thereof |
US9018347B2 (en) | 2010-02-04 | 2015-04-28 | Morphotek, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
US9023595B2 (en) | 2008-05-15 | 2015-05-05 | Morphotek, Inc. | Treatment of metastatic tumors |
WO2017180789A2 (en) | 2016-04-12 | 2017-10-19 | Blaze Bioscience, Inc. | Methods of treatment using chlorotoxin conjugates |
WO2017181149A1 (en) | 2016-04-15 | 2017-10-19 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
US10156559B2 (en) | 2012-12-10 | 2018-12-18 | Fred Hutchinson Cancer Research Center | Lipocalin fusion partners |
US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5905027A (en) * | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
US20060088899A1 (en) * | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
EP2018559A1 (en) * | 2006-04-25 | 2009-01-28 | Centre National de la Recherche Scientifique (CNRS) | Functionalization of gold nanoparticles with oriented proteins. application to the high-density labelling of cell membranes |
CA2943712C (en) * | 2007-07-30 | 2019-06-04 | The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Northern Arizona University | Methods and devices for the detection of biofilm |
JP5580205B2 (en) * | 2007-11-19 | 2014-08-27 | セレラ コーポレーション | Lung cancer markers and their use |
WO2009126835A2 (en) * | 2008-04-09 | 2009-10-15 | University Of Washington Techtransfer Invention Licensing | Magnetic nanoparticle and method for imaging t cells |
US8697375B2 (en) * | 2008-09-02 | 2014-04-15 | University Of Maryland, Baltimore | In vivo biofilm infection diagnosis and treatment |
WO2013166487A1 (en) | 2012-05-04 | 2013-11-07 | Yale University | Highly penetrative nanocarriers for treatment of cns disease |
US9784730B2 (en) | 2013-03-21 | 2017-10-10 | University Of Washington Through Its Center For Commercialization | Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5905027A (en) | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
WO2000062807A1 (en) | 1999-04-21 | 2000-10-26 | The Uab Research Foundation | Diagnosis and treatment of neuroectodermal tumors |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3407582A1 (en) | 1984-03-01 | 1985-09-05 | Dornier System Gmbh, 7990 Friedrichshafen | CIRCUIT ARRANGEMENT FOR A CONTROL LOOP |
US6130101A (en) * | 1997-09-23 | 2000-10-10 | Molecular Probes, Inc. | Sulfonated xanthene derivatives |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
CA2384429A1 (en) * | 1999-09-14 | 2001-03-22 | Michael K. Bahr | Magnetic nanoparticles having biochemical activity, method for the production thereof and their use |
AU4305101A (en) * | 1999-11-22 | 2001-06-04 | Research Foundation Of The State University Of New York, The | Magnetic nanoparticles for selective therapy |
DE10020376A1 (en) * | 2000-04-26 | 2001-11-08 | Inst Zelltechnologie E V | Dynamic markers |
AU2002345959A1 (en) | 2001-06-26 | 2003-01-08 | Uab Research Foundation | Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling |
US6972326B2 (en) * | 2001-12-03 | 2005-12-06 | Molecular Probes, Inc. | Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes |
US20060088899A1 (en) | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
AU2003237347B2 (en) | 2002-05-31 | 2009-07-23 | Transmolecular Inc. | Treatment of cell proliferative disorders with chlorotoxin |
US7560160B2 (en) * | 2002-11-25 | 2009-07-14 | Materials Modification, Inc. | Multifunctional particulate material, fluid, and composition |
US20040101822A1 (en) * | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
DE10328251A1 (en) | 2003-06-24 | 2005-01-13 | Toximed Gmbh | Pharmaceutical agent |
US20070275902A1 (en) | 2003-11-26 | 2007-11-29 | Transmolecular, Inc. | Treatment of Phosphatidylinositol Phospholipid Disorders |
US20080153746A1 (en) | 2004-04-06 | 2008-06-26 | Transmolecular, Inc. | Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers |
EP1756270B1 (en) | 2004-04-06 | 2010-03-03 | Transmolecular, Inc. | Diagnosis and treatment of myeloid and lymphoid cell cancers with chlorotoxin or a derivative |
GB0422901D0 (en) | 2004-10-14 | 2004-11-17 | Ares Trading Sa | Lipocalin protein |
GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
US7462446B2 (en) * | 2005-03-18 | 2008-12-09 | University Of Washington | Magnetic nanoparticle compositions and methods |
DE602006020710D1 (en) | 2005-04-22 | 2011-04-28 | Fred Hutchinson Cancer Res Foundation | FLUORESCENT CHLOROTOXIN CONJUGATE AND METHOD FOR THE INTRAOPERATIVE VIEW OF CANCER |
MX2008002149A (en) | 2005-08-18 | 2008-04-22 | Ambrx Inc | COMPOSITIONS OF tRNA AND USES THEREOF. |
US20070237714A1 (en) | 2006-03-31 | 2007-10-11 | Alvarez Vernon L | Diagnosis and treatment of tumors |
WO2007137163A2 (en) | 2006-05-19 | 2007-11-29 | Georgia Tech Research Corporation | Abc transporter ligand |
CN100564517C (en) | 2006-09-21 | 2009-12-02 | 武汉大学 | A kind of anti-glioma peptide of scorpion and its production and application |
CN101003788A (en) | 2006-09-21 | 2007-07-25 | 武汉大学 | Anti tumor translocation peptide of scorpion, preparation method and application |
US7825093B2 (en) | 2006-10-25 | 2010-11-02 | Amgen Inc. | Methods of using OSK1 peptide analogs |
US20090004105A1 (en) | 2007-06-27 | 2009-01-01 | Zhen Cheng | Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin |
AU2008285364A1 (en) | 2007-08-07 | 2009-02-12 | Transmolecular, Inc. | Chlorotoxins as drug carriers |
EP2211913A4 (en) | 2007-10-12 | 2010-12-22 | Transmolecular Inc | Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors |
US8470607B2 (en) | 2008-03-20 | 2013-06-25 | Morphotek, Inc. | Inhibition of angiogenesis |
CN101270158B (en) | 2008-04-30 | 2010-12-22 | 武汉大学 | Target glioma resistant protein, preparation method and application |
JP2011520914A (en) | 2008-05-15 | 2011-07-21 | トランスモレキュラー, インコーポレイテッド | Treatment of metastatic tumor |
EP2313430B1 (en) | 2008-06-24 | 2018-05-02 | Technische Universität München | Muteins of hngal and related proteins with affinity for a given target |
US20100098637A1 (en) | 2008-09-23 | 2010-04-22 | The Regents Of The University Of Michigan | Dye-loaded nanoparticle |
CN101381405B (en) | 2008-09-24 | 2011-07-27 | 武汉摩尔生物科技有限公司 | Genetic engineering tumor targeting KCT-W1 polypeptides and preparation method and application |
US10191060B2 (en) | 2009-11-09 | 2019-01-29 | University Of Washington | Functionalized chromophoric polymer dots and bioconjugates thereof |
CN101921769B (en) | 2010-01-11 | 2012-07-25 | 山西大学 | Recombinant adenovirus, preparation method and application thereof |
WO2011094671A2 (en) | 2010-01-29 | 2011-08-04 | The Uab Research Foundation | N-terminally conjugated polypeptides for targeted therapy and diagnosis |
CN102844044B (en) | 2010-02-04 | 2016-10-26 | 摩尔弗泰克有限公司 | Catilan polypeptide and conjugate and application thereof |
CN101824084A (en) | 2010-04-08 | 2010-09-08 | 山西大学 | Targeting antiglioma protein and application thereof |
JP2013532126A (en) | 2010-05-11 | 2013-08-15 | フレッド ハッチンソン キャンサー リサーチ センター | Chlorotoxin variants, conjugates, and methods of using them |
DK2606061T3 (en) | 2010-08-16 | 2017-11-06 | Pieris Pharmaceuticals Gmbh | HEPCIDIN BINDING PROTEINS |
-
2006
- 2006-03-20 DE DE602006020710T patent/DE602006020710D1/en active Active
- 2006-03-20 ES ES06739100T patent/ES2360519T3/en active Active
- 2006-03-20 EP EP06739100A patent/EP1877428B1/en active Active
- 2006-03-20 AT AT06739100T patent/ATE502048T1/en active
- 2006-03-20 WO PCT/US2006/010170 patent/WO2006115633A2/en active Application Filing
- 2006-11-14 US US11/600,004 patent/US20070154965A1/en not_active Abandoned
-
2007
- 2007-08-31 US US11/897,721 patent/US8778310B2/en active Active
-
2014
- 2014-05-08 US US14/273,374 patent/US20140241993A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5905027A (en) | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
WO2000062807A1 (en) | 1999-04-21 | 2000-10-26 | The Uab Research Foundation | Diagnosis and treatment of neuroectodermal tumors |
Non-Patent Citations (5)
Title |
---|
BERLIER J.E. ET AL., J. HISTOCHEMISTRY AND CYTOCHEMISTRY, vol. 51, December 2003 (2003-12-01), pages 1699 - 1712 |
CITRIN D. ET AL., MOLECULAR CANCER THERAPEUTICS, vol. 3, no. 4, 2004, pages 481 - 488 |
DESHANE J. ET AL., J. BIOL. CHEM., vol. 278, no. 6, 7 February 2003 (2003-02-07), pages 4135 - 4144 |
SOROCEANU L. ET AL., CANCER RESEARCH, vol. 58, no. 21, 1 November 1998 (1998-11-01), pages 4871 - 4879 |
WEISSLEDER R. ET AL., NATURE MEDICINE, vol. 9, no. 1, 1 January 2003 (2003-01-01), pages 123 - 128 |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8778310B2 (en) | 2005-04-22 | 2014-07-15 | University Of Washington | Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer |
US11351274B2 (en) | 2006-02-24 | 2022-06-07 | Medibeacon Inc. | Methods of using optical agents |
US9283288B2 (en) | 2006-02-24 | 2016-03-15 | Medibeacon, Inc. | Methods of using optical agents |
WO2007106142A3 (en) * | 2006-02-24 | 2007-12-21 | Mallinckrodt Inc | Process for using optical agents |
US10695445B2 (en) | 2006-02-24 | 2020-06-30 | Medibeacon Inc. | Methods of using optical agents |
US10137207B2 (en) | 2006-02-24 | 2018-11-27 | Medibeacon, Inc. | Methods of using optical agents |
US11185597B2 (en) | 2006-02-24 | 2021-11-30 | Medibeacon, Inc. | Process for using optical agents |
WO2008139207A3 (en) * | 2007-05-16 | 2009-02-26 | Ge Healthcare As | Labelled hgf binding peptides for imaging |
CN101848734B (en) * | 2007-05-16 | 2013-08-28 | 通用电气医疗集团股份有限公司 | Labelled IIGF binding peptides for imaging |
WO2008139207A2 (en) * | 2007-05-16 | 2008-11-20 | Ge Healthcare As | Labelled hgf binding peptides for imaging |
US8529874B2 (en) | 2007-05-16 | 2013-09-10 | Ge Healthcare As | Peptide imaging agents |
WO2009021136A1 (en) * | 2007-08-07 | 2009-02-12 | Transmolecular, Inc. | Chlorotoxins as drug carriers |
EP2211913A2 (en) * | 2007-10-12 | 2010-08-04 | Transmolecular, Inc. | Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors |
EP2211913A4 (en) * | 2007-10-12 | 2010-12-22 | Transmolecular Inc | Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors |
EP2265630A2 (en) * | 2008-04-14 | 2010-12-29 | The General Hospital Corporation | Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma |
US10124077B2 (en) | 2008-04-14 | 2018-11-13 | The General Hospital Corporation | Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma |
JP2014132021A (en) * | 2008-04-14 | 2014-07-17 | General Hospital Corp | Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma |
US8829159B2 (en) | 2008-04-14 | 2014-09-09 | The General Hospital Corporation | Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma |
EP2265630A4 (en) * | 2008-04-14 | 2012-12-12 | Gen Hospital Corp | Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma |
JP2011521897A (en) * | 2008-04-14 | 2011-07-28 | ザ ジェネラル ホスピタル コーポレイション | Plectin-1 targeting agent for detection and treatment of ductal adenocarcinoma |
US9387265B2 (en) | 2008-04-14 | 2016-07-12 | The General Hospital Corporation | Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma |
US9023595B2 (en) | 2008-05-15 | 2015-05-05 | Morphotek, Inc. | Treatment of metastatic tumors |
US9603952B2 (en) | 2008-05-15 | 2017-03-28 | Morphotek, Inc. | Treatment of metastatic tumors |
US10183975B2 (en) | 2010-02-04 | 2019-01-22 | Morphotek, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
US9018347B2 (en) | 2010-02-04 | 2015-04-28 | Morphotek, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
US9234015B2 (en) | 2010-02-04 | 2016-01-12 | Morphotek, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
US9637526B2 (en) | 2010-02-04 | 2017-05-02 | Morphotek, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
US9944683B2 (en) | 2010-05-11 | 2018-04-17 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
CN103097403B (en) * | 2010-05-11 | 2017-04-19 | 弗雷德哈钦森癌症研究中心 | Chlorotoxin variants, conjugates, and methods for their use |
EP3165533A1 (en) * | 2010-05-11 | 2017-05-10 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates and methods for their use |
CN103097403A (en) * | 2010-05-11 | 2013-05-08 | 弗雷德哈钦森癌症研究中心 | Chlorotoxin variants, conjugates, and methods for their use |
US10822381B2 (en) | 2010-05-11 | 2020-11-03 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
EP2569330A4 (en) * | 2010-05-11 | 2013-11-13 | Hutchinson Fred Cancer Res | Chlorotoxin variants, conjugates, and methods for their use |
JP2013532126A (en) * | 2010-05-11 | 2013-08-15 | フレッド ハッチンソン キャンサー リサーチ センター | Chlorotoxin variants, conjugates, and methods of using them |
EP2569330A2 (en) * | 2010-05-11 | 2013-03-20 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
WO2011142858A2 (en) | 2010-05-11 | 2011-11-17 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
WO2013003507A1 (en) * | 2011-06-27 | 2013-01-03 | Morphotek, Inc. | Multifunctional agents |
US10156559B2 (en) | 2012-12-10 | 2018-12-18 | Fred Hutchinson Cancer Research Center | Lipocalin fusion partners |
WO2015042202A1 (en) | 2013-09-17 | 2015-03-26 | Blaze Bioscience, Inc. | Chlorotoxin conjugates and methods of use thereof |
US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
WO2017180789A2 (en) | 2016-04-12 | 2017-10-19 | Blaze Bioscience, Inc. | Methods of treatment using chlorotoxin conjugates |
WO2017181149A1 (en) | 2016-04-15 | 2017-10-19 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
Also Published As
Publication number | Publication date |
---|---|
EP1877428B1 (en) | 2011-03-16 |
ATE502048T1 (en) | 2011-04-15 |
ES2360519T3 (en) | 2011-06-06 |
WO2006115633A3 (en) | 2006-12-28 |
US20080279780A1 (en) | 2008-11-13 |
EP1877428A2 (en) | 2008-01-16 |
US20070154965A1 (en) | 2007-07-05 |
US8778310B2 (en) | 2014-07-15 |
US20140241993A1 (en) | 2014-08-28 |
DE602006020710D1 (en) | 2011-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8778310B2 (en) | Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer | |
Veiseh et al. | Tumor paint: a chlorotoxin: Cy5. 5 bioconjugate for intraoperative visualization of cancer foci | |
Kularatne et al. | Evaluation of novel prostate-specific membrane antigen-targeted near-infrared imaging agent for fluorescence-guided surgery of prostate cancer | |
Yang et al. | TMTP1, a novel tumor-homing peptide specifically targeting metastasis | |
He et al. | A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor | |
JP6793122B2 (en) | Intraoperative imaging | |
US20200174009A1 (en) | Ca ix - nir dyes and their uses | |
Boogerd et al. | Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: preclinical validation | |
Ma et al. | Anti-tumor effects of the peptide TMTP1-GG-D (KLAKLAK) 2 on highly metastatic cancers | |
JP2004501664A (en) | Isolation of cell-specific internalization peptides that infiltrate tumor tissue for targeted drug delivery | |
Citrin et al. | In vivo tumor imaging in mice with near-infrared labeled endostatin | |
Nagaya et al. | Molecularly targeted cancer combination therapy with near-infrared photoimmunotherapy and near-infrared photorelease with duocarmycin–antibody conjugate | |
US20230065522A1 (en) | Methods of cancer detection using parpi-fl | |
JP5836940B2 (en) | Soricidin derived peptides and methods for detection and drug delivery of TRPV-6 cancer | |
Bahng et al. | In vivo targeting of c-Met using a non-standard macrocyclic peptide in gastric carcinoma | |
He et al. | Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer | |
Tansi et al. | A fast and effective determination of the biodistribution and subcellular localization of fluorescent immunoliposomes in freshly excised animal organs | |
Kalot et al. | Lipoprotein interactions with water-soluble NIR-II emitting aza-BODIPYs boost the fluorescence signal and favor selective tumor targeting | |
Trac et al. | MRI Detection of Lymph Node Metastasis through Molecular Targeting of C–C Chemokine Receptor Type 2 and Monocyte Hitchhiking | |
Li et al. | c-Met-targeted near-infrared fluorescent probe for real-time depiction and dissection of perineural invasion and lymph node metastasis lesions in pancreatic ductal adenocarcinoma xenograft models | |
Cordova et al. | Aminopeptidase P mediated targeting for breast tissue specific conjugate delivery | |
Liu et al. | PEG2000-DBCO surface coating increases intracellular uptake of liposomes by breast cancer xenografts | |
Chopra | ZW800-1, a zwitterionic near-infrared fluorophore, and its cyclic RGD peptide derivative cyclo-(RGDyK)-ZW800-1 | |
US11555821B2 (en) | CA IX-NIR dyes and their uses | |
US20210060170A1 (en) | Photodynamic therapy composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006739100 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |